Total Allowable Error Table
Total Allowable Error Table (Updated 20 juin24)
Click here to view the table with target values prior to 20 juin24.
Analyte | Fluid | Method | Target Value | Source |
---|---|---|---|---|
17-Hydroxyprogesterone | Serum | ±2,0 nmol/L or 20% if > 10,0 nmol/L | 5 RCPA | |
3-Methoxytyramine (3MT) | Urine | ±15 nmol/L or ± 15% if > 100 nmol/L | 5 RCPA | |
4-hydroxy-3-methoxy-mandelate, (HMMA) | Urine | ±6 μmol/L or 15% if > 40 μmol/L | 5 RCPA | |
5HIAA | Urine | ±8 μmol/L or 20% if > 40 μmol/L | 5 RCPA | |
a1-Antitrypsin (α1AT) | Serum | ±0,10 g/L or 20% if > 0,5 g/L | 5 RCPA | |
Acetaminophen (Paracetamol) | Serum | ±15% or 3 µg/mL (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
Acetaminophen (Paracetamol) | Serum | ±15% or 2,5 µg/mL (greater) | 4 AAB | |
Acetaminophen (Paracetamol) | Serum | ±3,0 mg/L or 10% if > 30,0 mg/L | 5 RCPA | |
Activated Clotting Time (ACT) | Plasma | ±20% | 2 WSLH | |
Adrenaline | Urine | ±30 nmol/L or 30% if > 100 nmol/L | 5 RCPA | |
Adrenocorticotropic Hormone (ACTH) | Serum | ±2,0 pmol/L or 10% if > 20 pmol/L | 5 RCPA | |
Alanine Aminotransferase (ALT) | Serum | ±15% or 6 U/L (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
Alanine Aminotransferase (ALT) | Serum | ±20% | 4 AAB | |
Alanine Aminotransferase (ALT) | Serum | ±5 U/L or 12% if > 40 U/L | 5 RCPA | |
Albumin | Serum | ±8% | 1 CLIA, 2 WSLH, 3 CAP | |
Albumin | Body Fluids | ±10% | 2 WSLH | |
Albumin | Serum | ±10% | 4 AAB | |
Albumin | Serum, Body Fluids | ±2,0 g/L or 6% if > 33 g/L | 5 RCPA | |
Albumin | CSF | ±0,02 g/L or 20% if > 0,1 g/L | 5 RCPA | |
Albumin | Urine | ±4,0 mg/L or 20% if > 20,0 mg/L | 5 RCPA | |
Alcohol (ETOH) | Serum | ±20% | 1 CLIA, 2 WSLH | |
Alcohol (ETOH) | Serum | ±25% | 4 AAB | |
Alcohol (ETOH) | Serum | ±2,0 mmol/L or 10% if > 20 mmol/L | 5 RCPA | |
Aldosterone | Serum | ±24 pmol/L or 15% if > 160 pmol/L | 5 RCPA | |
Alkaline Phosphatase (ALP) | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP | |
Alkaline Phosphatase (ALP) | Serum | ±30% | 4 AAB | |
Alkaline Phosphatase (ALP) | Serum | ±15 U/L or 12% if > 125 U/L | 5 RCPA | |
Alpha 1 Antitrypsin | Serum | ±20% | 1 CLIA | |
Alpha-fetoprotein (AFP) | Serum | ±20% | 1 CLIA, 2 WSLH | |
Alpha-fetoprotein (AFP) | Serum | ±2 kIU/L or 12% if > 17 kIU/L | 5 RCPA | |
Aluminum | Serum | ±0,08 μmol/L or 20% if > 0,40 μmol/L | 5 RCPA | |
Amikacin | Serum | ±3 SD or 10% (greater) | 3 CAP | |
Amikacin | Serum | ±2 mg/L or 10% if > 19,9 mg/L | 5 RCPA | |
Aminolaevulinic Acid (ALA) | Urine | ±8 μmol/L or 25% if > 32 μmol/L | 5 RCPA | |
Amiodarone | Serum | ±0,1 mg/L or 10% if > 1,3 mg/L | 5 RCPA | |
Amitriptyline | Serum | ±3,0 μg/L or 10% if > 28,0 μg/L | 5 RCPA | |
Ammonia | Serum | ±5% or 10 µmol/L (greater) | 4 AAB | |
Ammonia | Serum | ±5 μmol/L or 10% if > 50 μmol/L | 5 RCPA | |
Amylase | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP | |
Amylase | Serum | ±30% | 4 AAB | |
Amylase | Body Fluids, Urine | ±30% | 2 WSLH | |
Amylase | Serum | ±10 U/L or 10% if > 100 U/L | 5 RCPA | |
Amylase | Body Fluids | ±20 U/L or 20% if > 100 U/L | 5 RCPA | |
Androstenedione | Serum | ±1,5 nmol/L or 15% if > 10 nmol/L | 5 RCPA | |
Angiotensin Converting Enzyme (ACE) | Serum | ±1,0 or 10% if > 10,0 U/L | 5 RCPA | |
Antinuclear antibody (ANA) | Serum | ±2 dilutions or positive or negative | 1 CLIA | |
Antistreptolysin O (ASO) | Serum | ±2 dilutions or positive or negative | 1 CLIA | |
Antithrombin, Functional (AT) | Plasma | ±10% or 25% if > 40% | 5 RCPA | |
Anti HIV (Human Immunodeficiency virus) | Serum | Reactive (positive) or nonreactive (negative) | 1 CLIA | |
Anti Xa | Plasma | ±25 ng/mL or 25% if > 100 ng/mL | 5 RCPA | |
Apolipoprotein A1 | Serum | ±0,2 g/L or 10% if > 2,0 g/L | 5 RCPA | |
Apolipoprotein B | Serum | ±0,2 g/L or 10% if > 2,0 g/L | 5 RCPA | |
Arsenic, Total | Urine | ±50 nmol/L or 10% if > 500 nmol/L | 5 RCPA | |
Arsenic, Total | WB | ±10 nmol/L or 10% if > 100 nmol/L | 5 RCPA | |
Aspartate Aminotransferase (AST) | Serum | ±15% or 6 U/L (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
Aspartate Aminotransferase (AST) | Serum | ±20% | 4 AAB | |
Aspartate Aminotransferase (AST) | Serum | ±5 U/L or 12% if > 40 U/L | 5 RCPA | |
Basophile, count | WB | ±3% or 30% if > 10% | 5 RCPA | |
Beta-2 microglobulin (B2M) | Serum | ±0,2 mg/L or 10% if > 2,0 mg/L | 5 RCPA | |
Beta Carotene | Serum | ±0,4 μmol/L or 25% if > 2,0 μmol/L | 5 RCPA | |
Bile Acids, Total | Serum | ±4 μmol/L or 10% if > 40 μmol/L | 5 RCPA | |
Bilirubin, Direct or Conjugated (DBIL) | Serum | ±0,4 mg/dL or 20% (greater) | 2 WSLH, 3 CAP | |
Bilirubin, Direct or Conjugated (DBIL) | Serum | ±3 μmol/L or 20% if > 15 μmol/L | 5 RCPA | |
Bilirubin, Neonatal (TBIL) | Serum | ±20% or 0,4 mg/dL (greater) | 4 AAB | |
Bilirubin, Neonatal (TBIL) | Serum | ±8 μmol/L or 10% if > 80 μmol/L | 5 RCPA | |
Bilirubin, Total | Serum | ±20% or 0,4 mg/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
Bilirubin, Total | Serum | ±3 μmol/L or 12% if > 25 μmol/L | 5 RCPA | |
Bilirubin, Total | CSF | ±0,12 μmol/L or 20% if > 0,6 μmol/L | 5 RCPA | |
B-natriuretic Peptide (BNP) | Serum | ±30% | 1 CLIA, 2 WSLH | |
B-natriuretic Peptide (BNP) | Serum | ±2 SD or 25% (greater) | 4 AAB | |
B-natriuretic Peptide (BNP) | Serum | ±20 ng/L or 20% if > 100 ng/L | 5 RCPA | |
B-natriuretic Peptide, Pro (proBNP) | Serum | ±30% | 2 WSLH | |
B-natriuretic Peptide, Pro (proBNP) | Serum | ±25% | 4 AAB | |
B-natriuretic Peptide, Pro (proBNP) | Serum | ±25 ng/L or 20% if > 125 ng/L | 5 RCPA | |
C Peptide | Serum | ±0,15 nmol/L or 12% if > 1,25 nmol/L | 5 RCPA | |
C1 Inhibitor, Esterase (C1inh) | Serum | ±0,03 g/L or 15% if > ±0,2 g/L | 5 RCPA | |
Cadmium | Urine, WB | ±1 mg/dL or 15% | 2 WSLH | |
Cadmium | Urine, WB | ±3 nmol/L or 15% if > 20 nmol/L | 5 RCPA | |
Caffeine | Serum | ±3 SD or 10% (greater) | 3 CAP | |
Calcitonin | Serum | ±2 ng/L or 10% if > 20 ng/L | 5 RCPA | |
Calcium - Total | Serum | ±1,0 mg/dL | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
Calcium - Total | Urine | ±10% or 1 mg/dL | 2 WSLH | |
Calcium - Total | Serum | ±0,1 mmol/L or 4% if > 2,5 mmol/L | 5 RCPA | |
Calcium - Total | Urine | ±0,2 mmol/L or 10% if > 2,0 mmol/L | 5 RCPA | |
Calcium, Ionized | Serum | ±0,13 mmol/L | 2 WSLH | |
Calcium, Ionized | Serum | ±0,04 mmol/L or 4% if > 1,00 mmol/L | 5 RCPA | |
Cancer Antigen (CA) 125 | Serum | ±6 kU/L or 12% if > 50 kU/L | 5 RCPA | |
Cancer Antigen (CA) 15-3 | Serum | ±2 SD or 30% (greater) | 4 AAB | |
Cancer Antigen (CA) 15-3 | Serum | ±3 kU/L or 10% if > 30 kU/L | 5 RCPA | |
Cancer Antigen (CA) 19-9 | Serum | ±2 SD or 30% (greater) | 4 AAB | |
Cancer Antigen (CA) 19-9 | Serum | ±6 kU/L or 15% if > 40 kU/L | 5 RCPA | |
Cancer Antigen (CA) 19-9 | Body Fluids | ±12 kU/L or 30% if > 40 kU/L | 5 RCPA | |
Cancer Antigen (CA) 27,29 | Serum | ±2 SD or 30% (greater) | 4 AAB | |
Carbamazepine | Serum | ±20% or 1,0 µg/mL (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
Carbamazepine | Serum | ±25% | 4 AAB | |
Carbamazepine | Serum | ±0,5 mg/L or 10% if > 4,7 mg/L | 5 RCPA | |
Carbamazepine, Free | Serum | ±3 SD or 10% (greater) | 3 CAP | |
Carcinoembryonic Antigen (CEA) | Serum | ±15% or 1 ng/mL (greater) | 1 CLIA, 2 WSLH | |
Carcinoembryonic Antigen (CEA) | Serum | ±1,2 ng/mL or 20% | 4 AAB | |
Carcinoembryonic Antigen (CEA) | Serum | ±0,6 μg/L or 12% if > 5 μg/L | 5 RCPA | |
Carcinoembryonic Antigen (CEA) | Body Fluids | ±1,2 μg/L or 24% if > 5,0 μg/L | 5 RCPA | |
Carotenoids, Total | Serum | ±0,8 μmol/L or 25% if > 4,0 μmol/L | 5 RCPA | |
CD3+ Alpha-beta% | WB | ±4,5% to 15% if > 30% | 5 RCPA | |
CD3+% | WB | ±1,5% or 5% if > 30% | 5 RCPA | |
CD3x109/L | WB | ±0.02x109/L or 20% if > 0.1x109/L | 5 RCPA | |
CD4x109/L | WB | ±0.02x109/L or 20% if > 0.1x109/L | 5 RCPA | |
CD3+/CD4+% | WB | ±3% or 7,5% if > 40% | 5 RCPA | |
CD3+/CD8+% | WB | ±1,5% or 10% if > 15% | 5 RCPA | |
CD3-CD16+% | WB | ±2% or 20% if > 10% | 5 RCPA | |
CD3-CD56+% | WB | ±2% or 20% if > 10% | 5 RCPA | |
CD3-CD16+56+% | WB | ±2% or 20% if > 10% | 5 RCPA | |
CD8x109/L | WB | ±0.02x109/L or 20% if > 0.1x109/L | 5 RCPA | |
CD19+% | WB | ±2% or 20% if > 10% | 5 RCPA | |
CD19x109/L | WB | ±0.02x109/L or 20% if > 0.1x109/L | 5 RCPA | |
CD34+, % | WB | ±0,05% or 25% if > 0,3% | 5 RCPA | |
CD34+, Total | WB | ±5 μL or 25% if > 20 μL | 5 RCPA | |
Ceruloplasmin | Serum | ±0,03 g/L or 15% if > 0,2 g/L | 5 RCPA | |
Chloride | Serum | ±5% | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
Chloride | Urine | ±10% | 2 WSLH | |
Chloride | Serum | ±3 mmol/L or 3% if > 100 mmol/L | 5 RCPA | |
Chloride | Sweat | ±2,0 mmol/L or 5% if > 40 mmol/L | 5 RCPA | |
Chloride | Urine | ±4,0 mmol/L or 10% if > 40 mmol/L | 5 RCPA | |
Cholesterol, HDL | Serum | ±20% or 6 mg/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
Cholesterol, HDL | Serum | ±30% | 4 AAB | |
Cholesterol, HDL | Serum | ±0,1 mmol/L or 12% if > 0,8 mmol/L | 5 RCPA | |
Cholesterol, LDL | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP | |
Cholesterol, LDL | Serum | ±30% | 4 AAB | |
Cholesterol, LDL | Serum | ±0,2 mmol/L or 10% if > 2,0 mmol/L | 5 RCPA | |
Cholesterol, Total | Serum | ±10% | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
Cholesterol, Total | Body Fluids | ±10% | 2 WSLH | |
Cholesterol, Total | Serum | ±0,3 mmol/L or 6% if > 5,0 mmol/L | 5 RCPA | |
Cholesterol, Total | Body Fluids | ±0,3 mmol/L or 12% if > 2,5 mmol/L | 5 RCPA | |
Cholinesterase | Serum | ±500 U/L or 10% if > 5000 U/L | 5 RCPA | |
Chromium | Serum, Urine, WB | ±3 nmol/L or 12% if > 25 nmol/L | 5 RCPA | |
Clozapine | Serum | ±12 μg/L or 12% if > 100 μg/L | 5 RCPA | |
CO2, Carbon Dioxide (Bicarbonate) | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
CO2, Carbon Dioxide (Bicarbonate) | Serum | ±2,0 mmol/L or 10% if > 20,0 mmol/L | 5 RCPA | |
Cobalt | Plasma | ±1 nmol/L or 10% if > 10 nmol/L | 5 RCPA | |
Cobalt | Urine | ±2 nmol/L or 10% if > 20 nmol/L | 5 RCPA | |
Cobalt | WB | ±2 nmol/L or 10% if > 10 nmol/L | 5 RCPA | |
Compatibility testing | Serum | 100% accuracy | 1 CLIA | |
Complement C3 | Serum | ±15% | 1 CLIA | |
Complement C3 | Serum | ±0,10 g/L or 10% if > 1,0 g/L | 5 RCPA | |
Complement C4 | Serum | ±20% or 5 mg/dL (greater) | 1 CLIA | |
Complement C4 | Serum | 0,02 g/L or 10% if > 0,2 g/L | 5 RCPA | |
Conductivity | Sweat | ±2 mmol/L or 5% if > 50 mmol/L | 5 RCPA | |
Copper | Serum | ±1,6 μmol/L or 8% if > 20,0 μmol/L | 5 RCPA | |
Copper | Urine | ±0,05 μmol/L or 10% if > 0,50 μmol/L | 5 RCPA | |
Cortisol | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP | |
Cortisol | Serum | ±25% | 4 AAB | |
Cortisol | Serum | ±15 nmol/L or 15% if > 100 nmol/L | 5 RCPA | |
Cortisol | Urine | ±30 nmol/L or 15% if > 200 nmol/L | 5 RCPA | |
C-Reactive protein (CRP) | Serum | ±30% or 2 SD (greater) | 4 AAB | |
C-Reactive protein (CRP) | Serum | ±0,8 mg/L or 20% if > 4,0 mg/L | 5 RCPA | |
C-Reactive protein (CRP), High Sensitivity | Serum | ±30% or 1 mg/L (greater) | 1 CLIA, 2 WSLH, 4 AAB | |
C-Reactive protein (CRP), High Sensitivity | Serum | ±0,6 mg/L or 20% if > 3,0 mg/L | 5 RCPA | |
Creatine Kinase (CK) | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP | |
Creatine Kinase (CK) | Serum | ±30% | 4 AAB | |
Creatine Kinase (CK) | Serum | ±15 U/L or 12% if > 125 U/L | 5 RCPA | |
Creatine Kinase Isoenzyme (CKMB) | Serum | ±25% or 3 ng/mL (greater) or MB elevated (presence or absence) | 1 CLIA, 2 WSLH | |
Creatine Kinase Isoenzyme (CKMB) | Serum | ±3 U/L or 3 μg/L or 20% if > 15 U/L or 15 μg/L | 5 RCPA | |
Creatinine | Serum | ±10% or 0,2 mg/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
Creatinine | Body Fluids, Urine | ±17% or 0,3 mg/dL | 2 WSLH | |
Creatinine | Serum | ±0,3 mg/dL or 15% (greater) | 4 AAB | |
Creatinine | Serum, Urine | ±17% | 4 AAB | |
Creatinine | Serum | ±8,0 μmol/L or 8% if > 100 μmol/L | 5 RCPA | |
Creatinine | Body Fluids | ±16,0 μmol/L or 16% if > 100 μmol/L | 5 RCPA | |
Creatinine | Urine | ±0,5 mmol/L or 10% if > 5,0 mmol/L | 5 RCPA | |
Cyclosporine | Serum | ±10 μg/L or 10% if > 100 μg/L | 5 RCPA | |
d-Dimer | Plasma | ±15% | 2 WSLH | |
d-Dimer | Plasma | ±2 SD or 30% (greater) | 4 AAB | |
d-Dimer | Plasma | automated DD | ±0,25 DD mg/L or 50% if > 0,5 DD mg/L | 5 RCPA |
d-Dimer | Plasma | automated FEU | ±0,5 FEU mg/L or 50% if > 1,0 FEU mg/L | 5 RCPA |
DHEA Sulfate | Serum | ±30% or 2 SD (greater) | 4 AAB | |
DHEA Sulfate | Serum | ±1,2 μmol/L or 12% if > 10 μmol/L | 5 RCPA | |
Digoxin | Serum | ±15% or 0,2 ng/mL (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
Digoxin | Serum | ±0,2 ng/dL or 20% (greater) | 4 AAB | |
Digoxin | Serum | ±0,2 μg/L or 10% if > 1,6 μg/L | 5 RCPA | |
Digoxin, Free | Serum | ±3 SD or 10% (greater) | 3 CAP | |
Dihydropyrimidine dehydrogenase (DPYD) Free | Urine | ±15 nmol/L or 15% if > 80 nmol/L | 5 RCPA | |
Direct Thrombin Inhibitor, (DTI) | Plasma | ±25 ng/mL or 25% if >100 ng/mL | 5 RCPA | |
Disopyramide | Serum | ±3 SD or 10% (greater) | 3 CAP | |
Dopamine | Urine | ±0,2 μmol/L or 10% if > 2,0 μmol/L | 5 RCPA | |
Eosinophils, count | WB | ±3% or 30% if > 10% | 5 RCPA | |
Erythrocyte Sedimentation Rate (ESR) | WB | ±3,0 mm/hr or 30% if > 10 mm/hr | 5 RCPA | |
Estradiol | Serum | ±30% | 1 CLIA, 2 WSLH, 4 AAB | |
Estradiol (Oestradiol) | Serum | ±25 pmol/L or 25% if > 100 pmol/L | 5 RCPA | |
Estriol, Unconjugated (Oestriol) | Serum | ±0,9 nmol/L or 15% if > 6,0 nmol/L | 5 RCPA | |
Ethosuximide | Serum | ±20% | 3 CAP | |
Factor II, V, VII, IX, X, XI, XII | Plasma | ±3 IU/dL or 30% if > 10 IU/dL | 5 RCPA | |
Factor VIII:C | Plasma | ±3% or 30% if > 10% | 5 RCPA | |
Fecal Occult Blood (FOBT) | Stool | ±15 ng/mL or 15% if > 100 ng/mL | 5 RCPA | |
Ferritin | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
Ferritin | Serum | ±4,0 μg/L or 15% if 27,0 μg/L | 5 RCPA | |
Fibrinogen | Plasma | ±20% | 1 CLIA, 2 WSLH, 4 AAB | |
Fibrinogen | Plasma | ±0,2 g/L or 25% if > 1,0 g/L | 5 RCPA | |
Fluconazole | Serum | ±2,0 mg/L or 10% if > 20 mg/L | 5 RCPA | |
Flucytosine | Serum | ±10 mg/L or 10% if > 100 mg/L | 5 RCPA | |
Folate | Serum | ±30% or 1 ng/mL (greater) | 1 CLIA, 2 WSLH, 4 AAB | |
Folate | Serum | ±1,5 nmol/L or 25% if > 6,0 nmol/L | 5 RCPA | |
Folate, RBC | WB | ±80 nmol/L or 20% if > 400 nmol/L | 5 RCPA | |
Follicle Stimulating Hormone (FSH) | Serum | ±18% or 2 IU/L (greater) | 1 CLIA, 2 WSLH, 4 AAB | |
Follicle Stimulating Hormone (FSH) | Serum | ±1,0 IU/L or 10% if > 10,0 IU/L | 5 RCPA | |
Fractional Carboxyhemoglobin | WB | ±1% or 20% if > 5% | 5 RCPA | |
Fractional Methemoglobin | WB | ±2% or 10% if > 20% | 5 RCPA | |
Fractional Oxyhemoglobin | WB | ±3% or 4% if > 75% | 5 RCPA | |
Fructosamine | Serum | ±15 μmol/L or 6% if > 250 μmol/L | 5 RCPA | |
Gamma glutamyl transferase (GGT) | Serum | ±15% or 5 U/L (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
Gamma glutamyl transferase (GGT) | Serum | ±2 SD or 15% (greater) | 4 AAB | |
Gamma glutamyl transferase (GGT) | Serum | ±5 U/L or 12% if > 40 U/L | 5 RCPA | |
Gastrin | Serum | ±10 pmol/L or 10% if > 100 pmol/L | 5 RCPA | |
Gentamicin | Serum | ±25% | 1 CLIA, 2 WSLH, 3 CAP | |
Gentamicin | Serum | ±25% or 1,0 µg/mL (greater) | 4 AAB | |
Gentamicin | Serum | ±0,2 mg/L or 10% if > 2,0 mg/L | 5 RCPA | |
Glucose | Serum | ±8% or 6 mg/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
Glucose | Body Fluids, CSF, Urine | ±10% | 2 WSLH | |
Glucose | WB | ±20% or 15 mg/dL | 2 WSLH | |
Glucose | Serum | ±6 mg/dL or 10% (greater) | 4 AAB | |
Glucose | WB | ±6 mg/dL or 20% (greater) | 4 AAB | |
Glucose | Serum, Body Fluids | ±0,4 mmol/L or 8% if > 5,0 mmol/L | 5 RCPA | |
Glucose | CSF | ±0,2 mmol/L or 10% if > 2,0 mmol/L | 5 RCPA | |
Glucose | Urine | ±1,0 mmol/L or 10% if > 10,0 mmol/L | 5 RCPA | |
Glucose-6-phosphate-1-dehydrogenase (G6PD) | WB | ±3,0 U/g Hb or 30% if > 10 U/g Hb | 5 RCPA | |
Growth Hormone | Serum | ±1,0 mU/L or 15% if > 7,0 mU/L | 5 RCPA | |
Haptoglobin | Serum | ±0,1 g/L or 10% if > 0,8 g/L | 5 RCPA | |
Hematocrit | WB | ±4% | 1 CLIA, 2 WSLH | |
Hematocrit | WB | ±6 mg/dL or 20% (greater) | 4 AAB | |
Hematocrit | WB | ±4% or 20% if > 20% | 5 RCPA | |
Hemoglobin | WB | ±4% | 1 CLIA, 2 WSLH | |
Hemoglobin | WB | ±7% | 4 AAB | |
Hemoglobin | WB | ±5 g/L or 5% if > 100 g/L | 5 RCPA | |
Hemoglobin A1c (Glycohemoglobin) | WB | ±8% | 1 CLIA, 2 WSLH | |
Hemoglobin A1c (Glycohemoglobin) | WB | ±5% | 4 AAB | |
Hemoglobin A1c (Glycohemoglobin) | WB | IFCC | ±4 mmol/mol or 8% if > 45 mmol/mol | 5 RCPA |
Hemoglobin A1c (Glycohemoglobin) | WB | NGSP | ±0,4% or 6% if > 6,7% | 5 RCPA |
Hemoglobin, A2 | WB | ±0,3% or 10% if > 2,0 | 5 RCPA | |
Hemoglobin, F | WB | ±0,5% or 30% if > 1,5% | 5 RCPA | |
Hemoglobin, Variant | WB | ±4% or 20% if > 20,0% | 5 RCPA | |
Hemolysis, Serum Index | Serum | ±8 mg/dL or 10% if > 80 mg/dL | 5 RCPA | |
Hepatitis (Anti-HBc, HBsAg, HBeAg, Anti-HCV) | Serum | Reactive (positive) or nonreactive (negative) | 1 CLIA, 2 WSLH | |
Hepatitis, Surface Antibody (Anti-HBs) | Serum | Reactive (positive) or nonreactive (negative) | 1 CLIA, 2 WSLH | |
Homocysteine | Serum | ±30% | 4 AAB | |
Homocysteine | Serum | ±1,5 μmol/L or 10% if > 15 μmol/L | 5 RCPA | |
Homovanillic Acid (HVA) | Urine | ±6 μmol/L or 15% if > 40 μmol/L | 5 RCPA | |
Human Chorionic Gonadotropin (HCG) | Serum | ±18% or 3 mIU/mL (greater) or positive or negative | 1 CLIA, 2 WSLH, 3 CAP | |
Human Chorionic Gonadotropin (HCG) | Serum | ±18% or 2 SD (greater) | 4 AAB | |
Human Chorionic Gonadotropin (HCG) | Serum | ±1,0 IU/L or 10% if > 10,0 IU/L | 5 RCPA | |
Human Chorionic Gonadotropin (HCG) | Urine | ±5,0 IU/L or 10% if > 50 IU/L | 5 RCPA | |
Hydroxyitraconazole | Serum | ±0,2 mg/L or 10% if > 2,0 mg/L | 5 RCPA | |
Icterus, Serum Index | Serum | ±6,0 μmol/L or 25% if > 25,0 μmol/L | 5 RCPA | |
IgA | Serum | ±20% | 1 CLIA | |
IgA | Serum | ±0,06 g/L or 10% if > 0,6 g/L | 5 RCPA | |
IgD | Serum | ±0,2 g/L or 20% if > 1,0 g/L | 5 RCPA | |
IgE | Serum | ±20% | 1 CLIA | |
IgE | Serum | ±20 kU/L or 20% if > 100 kU/L | 5 RCPA | |
IgG | Serum | ±20% | 1 CLIA | |
IgG | Serum | ±25% | 4 AAB | |
IgG | Serum | ±0,6 g/L or 10% if > 6 g/L | 5 RCPA | |
IgG | CSF | ±0,02 g/L or 20% if > 0,1 g/L | 5 RCPA | |
IgM | Serum | ±20% | 1 CLIA | |
IgM | Serum | ±0,08 g/L or 15% If > 0,5 g/L | 5 RCPA | |
Immature granulocytes (IG's) | WB | ±3% or 30% if > 10% | 5 RCPA | |
Infectious mononucleosis | Serum | ±2 dilutions or positive or negative | 1 CLIA, 2 WSLH | |
INR | Plasma | ±15% | 1 CLIA, 2 WSLH, 4 AAB | |
INR | Plasma | ±0,3 ratio or 15% if > 2,0 ratio | 5 RCPA | |
Insulin | Serum | ±6 mU/L or 12% if > 5 mU/L | 5 RCPA | |
Insulin-like Growth Factor (IGF-1) | Serum | ±3 nmol/L or 12% if > 25 nmol/L | 5 RCPA | |
Insulin-like Growth Factor Binding Protein (IGFBP-3) | Serum | ±15 nmol/L or 15% if > 100 nmol/L | 5 RCPA | |
Iodine | Urine | ±80 nmol/L or 10% if > 800 nmol/L | 5 RCPA | |
Iron (Fe) | Serum | ±15% | 1 CLIA, 2 WSLH, 3 CAP | |
Iron (Fe) | Serum | ±20% | 4 AAB | |
Iron (Fe) | Serum, Urine | ±3,0 μmol/L or 12% if > 25,0 μmol/L | 5 RCPA | |
Iron Binding Capacity, Total (IBC) | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
Iron Binding Capacity, Total (IBC) | Serum, Urine | ±20% | 4 AAB | |
Iron Binding Capacity, Total (IBC) | Serum | ±4 μmol/L or 8% if > 50,0 μmol/L | 5 RCPA | |
Iron Binding Capacity, Unsaturated (UIBC) | Serum | ±20% | 2 WSLH | |
Itraconazole | Serum | ±0,1 mg/L or 10% if > 1,0 mg/L | 5 RCPA | |
Lactate | Serum | ±0,2 mmol/L | 2 WSLH | |
Lactate | CSF | ±10% | 2 WSLH | |
Lactate | Serum | ±0,4 mmol/L or 3 SD (greater) | 3 CAP, 4 AAB | |
Lactate | Serum | ±0,5 mmol/L or 12% if > 4,0 mmol/L | 5 RCPA | |
Lactate | CSF | ±0,3 mmol/L or 10% if > 3,0 mmol/L | 5 RCPA | |
Lactate | Body Fluids | ±1,0 mmol/L or 25% if > 4,0 mmol/L | 5 RCPA | |
Lactate Dehydrogenase (LD, LDH) | Serum | ±15% | 1 CLIA, 2 WSLH, 3 CAP | |
Lactate Dehydrogenase (LD, LDH) | Body Fluids | ±20% | 2 WSLH | |
Lactate Dehydrogenase (LD, LDH) | Serum | ±20% | 4 AAB | |
Lactate Dehydrogenase (LD, LDH) | Serum, Body Fluids | ±20 U/L or 8% if > 250 U/L | 5 RCPA | |
Lead (Pb) | WB | ±10% or 2 µg/dL (greater) | 1 CLIA, 2 WSLH | |
Lead (Pb) | WB | ±4 µg/dL or 10% (greater) | 4 AAB | |
Lead (Pb) | Urine | ±50 nmol/L or 10% if > 500 nmol/L | 5 RCPA | |
Lead (Pb) | WB | ±0,05 μmol/L or 10% if > 0,50 μmol/L | 5 RCPA | |
Lidocaine | Serum | ±3 SD or 10% (greater) | 3 CAP | |
Lipase | Serum | ±30% | 2 WSLH, 3 CAP, 4 AAB | |
Lipase | Serum | ±12 U/L or 20% if > 60 U/L | 5 RCPA | |
Lipase | Body Fluids | ±24 U/L or 40% if > 60 U/L | 5 RCPA | |
Lipemia, Serum Index | Serum | ±26 mg/dL or 10% if > 263 mg/dL | 5 RCPA | |
Lipoprotein (a) | Serum | ±0,06 g/L or 20% if > 0,3 g/L | 5 RCPA | |
Lithium | Serum | ±15% or 0,3 mmol/L (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
Lithium | Serum | ±0,3 mmol/L or 20% (greater) | 4 AAB | |
Lithium | Serum | ±0,2 mmol/L or 10% if > 2,0 mmol/L | 5 RCPA | |
Luteinizing Hormone (LH) | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
Luteinizing Hormone (LH) | Serum | ±1,5 IU/L or 15% if > 10,0 IU/L | 5 RCPA | |
Lymphocytes, count | WB | ±2% or 20% if > 10% | 5 RCPA | |
Magnesium | Serum | ±15% | 1 CLIA, 2 WSLH, 3 CAP | |
Magnesium | Urine | ±25% | 2 WSLH | |
Magnesium | Serum | ±25% | 4 AAB | |
Magnesium | Serum, WB | ±0,1 mmol/L or 8% if > 1,25 mmol/L | 5 RCPA | |
Magnesium | Urine | ±0,3 mmol/L or 15% if > 2,0 mmol/L | 5 RCPA | |
Magnesium | Urine | ±0,1 mmol/L or 8% if > 1,25 mmol/L | 5 RCPA | |
Manganese | Serum | ±0,1 nmol/L or 8% if | 5 RCPA | |
Manganese | Urine | ±3 nmol/L or 12% if > 25 nmol/L | 5 RCPA | |
Manganese | WB | ±30 nmol/L or 12% if > 250 nmol/L | 5 RCPA | |
Mean corpuscular hemoglobin (MCH) | WB | ±2 pg or 10% if > 20 pg | 5 RCPA | |
Mean corpuscular hemoglobin concentration (MCHC) | WB | ±30 g/L or 10% if > than 300 g/L | 5 RCPA | |
Mean corpuscular volume (MCV) | WB | ±5 fL or 10% if > 50 fL | 5 RCPA | |
Mean platelet volume (MPV) | WB | ±2 fL or 20% if > 10 fL | 5 RCPA | |
Metanephrine | Plasma | ±75 pmol/L or 15% if > 500 pmol/L | 5 RCPA | |
Metanephrine | Urine | ±0,2 μmol/L or 20% if > 1,0 μmol/L | 5 RCPA | |
Metanephrine, Free | Urine | ±30 nmol/L or 30% if > 100 nmol/L | 5 RCPA | |
Methemoglobin | WB | ±0,003 | 2 WSLH | |
Methotrexate | Serum | ±3 SD or 10% (greater) | 3 CAP | |
Methotrexate | Serum | ±0,10 μg/L or 10% if > 1,00 μmol/L | 5 RCPA | |
Methyoxytyramine | Plasma | ±36 pmol/L or 30% if > 120 pmol/L | 5 RCPA | |
Mercury | Serum | ±30% or 3 ug/L | 2 WSLH | |
Mercury | Serum, Urine, WB | ±9 nmol/L or 15% if > 60 nmol/L | 5 RCPA | |
Microalbumin | Urine | ±10% | 2 WSLH | |
Microalbumin | Urine | ±30% | 4 AAB | |
Monocytes, count | WB | ±3% or 30% if > 10% | 5 RCPA | |
Mycophenolate | Serum | ±0,10 μg/L or 10% if > 1,00 mg/L | 5 RCPA | |
Myoglobin | Serum | ±2 SD or 30% (greater) | 4 AAB | |
N-Acetylprocainamide (NAPA) | Serum | ±25% | 3 CAP | |
Neuron-specific enolase (NSE) | Serum | ±2 μg/L or 10% if > 20 μg/L | 5 RCPA | |
Neutrophil, count | WB | automated | ±1% or 10% if > 10,0% | 5 RCPA |
Nickel | Urine | ±40 nmol/L or 10% if > 400 nmol/L | 5 RCPA | |
Noradrenaline | Urine | ±75 nmol/L or 15% if > 500 nmol/L | 5 RCPA | |
Normetanephrine | Plasma | ±200 pmol/L or 20% if > 1000 pmol/L | 5 RCPA | |
Normetanephrine | Urine | ±0,4 μmol/L or 20% if > 2,0 μmol/L | 5 RCPA | |
Normetanephrine, Free | Urine | ±40 nmol/L or 20% if > 200 nmol/L | 5 RCPA | |
Nortriptyline | Serum | ±3,0 μg/L or 10% if > 26,0 μg/L | 5 RCPA | |
N-Telopeptides | Urine | ±80 nmolBCE/L or 10% if > 700 nmolBCE/L | 5 RCPA | |
Osmolality | Urine | ±10% | 2 WSLH | |
Osmolality | Serum, Body Fluids | ±8 mmol/kg or 3% if > 266 mmol/kg | 5 RCPA | |
Osmolality | Urine | ±6 mmol/kg or 2% if > 300 mmol/kg | 5 RCPA | |
Pancreatic Amylase | Serum | ±30% | 3 CAP | |
Parathyroid hormone (PTH) | Serum | ±30% | 1 CLIA, 2 WSLH, 4 AAB | |
Parathyroid Hormone (PTH) | Serum | ±1,0 pmol/L or 12% if > 8,0 pmol/L | 5 RCPA | |
Partial thromboplastin time (PTT), (aPTT) | Plasma | ±15% | 1 CLIA, 2 WSLH, 4 AAB | |
Partial thromboplastin time (PTT), (aPTT) | Plasma | ±10 sec or 25% if > 40 sec | 5 RCPA | |
pCO2 | WB | ±8% or 5 mmHg (greater) | 1 CLIA, 2 WSLH, 4 AAB | |
pCO2 | WB | ±2 mm Hg or 6% if > 34,0 mm Hg | 5 RCPA | |
pH | WB | ±0,04 | 1 CLIA, 2 WSLH, 4 AAB, 5 RCPA | |
pH | Body Fluids | ±0,5 | 2 WSLH | |
pH | Body Fluids | ±0,02 | 5 RCPA | |
Phenobarbital | Serum | ±15% or 2 µg/mL (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
Phenobarbital | Serum | ±20% | 4 AAB | |
Phenobarbitone | Serum | ±0,7 mg/L or 10% if > 7,0 mg/L | 5 RCPA | |
Phenytoin | Serum | ±15% or 2 µg/mL (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
Phenytoin | Serum | ±25% | 4 AAB | |
Phenytoin | Serum | ±0,8 mg/L or 10% if > 7,6 mg/L | 5 RCPA | |
Phenytoin, Free | Serum | ±3 SD or 10% (greater) | 3 CAP | |
Phosphate | Serum | ±0,06 mmol/L or 8% if > 0,75 mmol/L | 5 RCPA | |
Phosphate | Urine | ±3 mmol/L or 15% if > 20 mmol/L | 5 RCPA | |
Phosphorus | Serum | ±10% or 0,3 mg/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
Phosphorus | Urine | ±15% or 0,5 mg/dL | 2 WSLH | |
Platelet count | WB | ±25% | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
Platelet count | WB | ±25x109/L or 25% If > 100x109/L | 5 RCPA | |
pO2 | WB | ±15% or 15 mmHg (greater) | 1 CLIA, 2 WSLH | |
pO2 | WB | ±5 mm Hg or 6% if > 83 mm Hg | 5 RCPA | |
Porphobilinogen | Urine | ±5 μmol/L or 25% if > 20 μmol/L | 5 RCPA | |
Porphyrin, Total | Plasma | ±4 nmol/L or 20% if > 20 nmol/L | 5 RCPA | |
Porphyrin, Total | Urine | ±60 nmol/ or 20% if > 300 nmol/L | 5 RCPA | |
Porphyrin, Total | Fecal | ±40 μmol/kg or 20% if > 200 μmol/kg | 5 RCPA | |
Porphyrin, Total RBC | WB | ±0,4 μmol/Lrc or 20% if > 2,0 μmol/Lrc | 5 RCPA | |
Posaconazole | Serum | ±0,1 mg/L or 10% if > 1,0 mg/L | 5 RCPA | |
Potassium (K) | Serum | ±0,3 mmol/L | 1 CLIA, 2 WSLH, 3 CAP | |
Potassium (K) | Urine | ±10% | 2 WSLH | |
Potassium (K) | Serum | ±0,5 mmol/L | 4 AAB | |
Potassium (K) | Serum | ±0,2 mmol/L or 5% if > 4,0 mmol/L | 5 RCPA | |
Potassium (K) | Body Fluids | ±0,4 mmol/L or 10% if > 4 mmol/L | 5 RCPA | |
Potassium (K) | Urine | ±2 mmol/L or 10% > 20 mmol/L | 5 RCPA | |
Prealbumin | Serum | ±5,0 mg/dL or 25% (greater) | 3 CAP | |
Prealbumin | Serum | ±25% | 4 AAB | |
Prealbumin | Serum | ±0,04 g/L or 20% if > 0,2 g/L | 5 RCPA | |
Primidone | Serum | ±25% | 3 CAP | |
Pro B-natriuretic Peptide (proBNP) | Serum | ±30% | 1 CLIA | |
Procainamide | Serum | ±25% | 3 CAP | |
Procalcitonin | Serum | ±0,05 ng/mL or 30% if > 0,15 ng/mL | 5 RCPA | |
Progesterone | Serum | ±25% | 1 CLIA, 2 WSLH, 4 AAB | |
Progesterone | Serum | ±2 nmol/L or 15% if > 10 nmol/L | 5 RCPA | |
Prolactin | Serum | ±20% | 1 CLIA, 2 WSLH, 4 AAB | |
Prolactin | Serum | ±40 mIU/L or 10% if > 400 mIU/L | 5 RCPA | |
Prostate Specific Antigen (PSA) | Serum | ±20% or 0,2 ng/mL (greater) | 1 CLIA, 2 WSLH | |
Prostate Specific Antigen (PSA) | Serum | ±0,9 ng/mL or 30% | 4 AAB | |
Prostate Specific Antigen (PSA) | Serum, Urine | ±0,4 μg/L or 8% if > 5,0 μg/L | 5 RCPA | |
Prostate Specific Antigen (PSA), Free | Serum | ±30% or 0,9 ng/mL | 2 WSLH | |
Prostate Specific Antigen (PSA), Free | Serum | ±0,9 ng/mL or 30% | 4 AAB | |
Prostate Specific Antigen (PSA), Free | Serum | ±0,2 μg/L or 15% if > 1,4 μg/L | 5 RCPA | |
Protein, Total | Serum | ±8% | 1 CLIA, 2 WSLH, 3 CAP | |
Protein, Total | Body Fluids, CSF, Urine | ±10% | 2 WSLH | |
Protein, Total | Serum | ±10% | 4 AAB | |
Protein, Total | Urine | ±44% | 4 AAB | |
Protein, Total | Serum, Body Fluids | ±3,0 g/L or 5% if > 60 g/L | 5 RCPA | |
Protein, Total | CSF | ±0,05 g/L or 10% if > 0,5 g/L | 5 RCPA | |
Protein, Total | Urine | ±0,1 g/L or 10% if > 1,00 g/L | 5 RCPA | |
Protein C, Functional | Plasma | ±12% or 20% if > 60% | 5 RCPA | |
Protein S, Free Antigen | Plasma | ±10% or 25% if > 40% | 5 RCPA | |
Protein S, Free Functional | Plasma | ±10% or 25% if > 40% | 5 RCPA | |
Protein S, Total Antigen | Plasma | ±10% or 25% if > 40% | 5 RCPA | |
Prothrombin Time (PT) | Serum | ±15% | 1 CLIA, 2 WSLH, 4 AAB | |
Prothrombin Time (PT) | Plasma | ±2,0 sec or 20% if > 10 sec | 5 RCPA | |
Quinidine | Serum | ±25% | 3 CAP | |
RBC, Red Cell count, Erythrocyte Count | WB | automated differential | ±4% | 1 CLIA, 2 WSLH |
RBC, Red Cell count, Erythrocyte Count | WB | quantitative | ±6% | 4 AAB |
Red Cell Distribution Width (RDW) | WB | 2% or 20% if > 10% | 5 RCPA | |
Reticulocyte count | WB | ±30% or 2 SD (greater) | 4 AAB | |
Reticulocyte count | WB | automated % | ±1,0% or 10% if > 10% | 5 RCPA |
Reticulocyte count | WB | automated absolute | ±10x109/L or 10% if > 100x109/L | 5 RCPA |
Reticulocyte count | WB | manual % | ±0,6% or 30% if > 2% | 5 RCPA |
Reticulocyte count | WB | manual absolute | ±21x109/L or 30% if > 70x109/L | 5 RCPA |
Rheumatoid Factor (RF) | Serum | ±2 dilutions or positive or negative | 1 CLIA, 2 WSLH | |
Rheumatoid Factor (RF) | Serum | ±12 IU/mL or 20% if > 60 IU/mL | 5 RCPA | |
Rubella | Serum | ±2 dilutions or positive or negative or immune or nonimmune | 1 CLIA, 2 WSLH | |
Salicylates | Serum | ±15% or 2 µg/mL (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
Salicylates | Serum | ±25% | 4 AAB | |
Salicylates | Serum | ±14 mg/L or 10% if > 143,0 mg/L | 5 RCPA | |
Selenium | Serum | ±0,18 μmol/L or 12% if > 1,50 μmol/L | 5 RCPA | |
Selenium | Urine | ±0,06 μmol/L or 12% if > 0,50 μmol/L | 5 RCPA | |
Selenium | WB | ±0,3 μmol/L or 12% if > 2,50 μmol/L | 5 RCPA | |
Serotonin | Urine | ±0,2 μmol/L or 20% if > 1,0 μmol/L | 5 RCPA | |
Sex hormone binding globulin (SHBG) | Serum | ±6 nmol/L or 12% if > 50 nmol/L | 5 RCPA | |
Sirolimus | Serum | ±0,5 μg/L or 10% if > 5,0 μg/L | 5 RCPA | |
Sodium (Na) | Serum | ±4 mmol/L | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
Sodium (Na) | Urine | ±10% or 4 mmol/L | 2 WSLH | |
Sodium (Na) | Serum | ±3 mmol/L or 2% if > 150 mmol/L | 5 RCPA | |
Sodium (Na) | Body Fluids | ±6 mmol/L or 4% if > 150 mmol/L | 5 RCPA | |
Sodium (Na) | Urine | ±4 mmol/L or 10% if > 40 mmol/L | 5 RCPA | |
Specific Gravity | Urine | ±0,010 | 2 WSLH, 4 AAB | |
T3 Free, (FT3) Triiodothyronine, Free | Serum | ±0,7 pmol/L or 20% if > 3,5 pmol/L | 5 RCPA | |
T3, Total Triiodothyronine | Serum | ±30% | 1 CLIA, 2 WSLH, 3 CAP | |
T3, Total Triiodothyronine | Serum | ±0,2 nmol/L or 15% if > 1,3 nmol/L | 5 RCPA | |
T3 Uptake | Serum | ±18% | 1 CLIA, 2 WSLH, 3 CAP | |
T4, Thyroxine | Serum | ±20% or 1,0 µg/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
T4, Thyroxine | Serum | ±12 nmol/L or 10% if > 120 nmol/L | 5 RCPA | |
T4, Free Thyroxine, (FT4) | Serum | ±15% or 0,3 ng/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
T4, Free Thyroxine, (FT4) | Serum | ±1,5 pmol/L or 12% if > 12,0 pmol/L | 5 RCPA | |
Tacrolimus | Serum | ±0,5 μg/L or 10% if > 5,0 μg/L | 5 RCPA | |
Testosterone | Serum | ±30% or 20 ng/dL (greater) | 1 CLIA, 2 WSLH, 4 AAB | |
Testosterone | Serum | ±0,4 nmol/L or 15% if > 2,7 nmol/L | 5 RCPA | |
Thallium | Serum, Urine | ±1 nmol/L or 10% if > 10 nmol/L | 5 RCPA | |
Thallium | WB | ±2 nmol/L or 10% if > 10 nmol/L | 5 RCPA | |
Theophylline | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP | |
Theophylline | Serum | ±25% | 4 AAB | |
Theophylline | Serum | ±0,5 mg/L or 10% if > 5,4 mg/L | 5 RCPA | |
Thrombin Time (TT) | Plasma | ±3,0 sec or 25% if > 12,0 sec | 5 RCPA | |
Thyroglobulin | Serum | ±0,2 μg/L or 12% if > 1,7 μg/L | 5 RCPA | |
Thyroid stimulating Hormone (TSH) | Serum | ±20% or 0,2 mIU/L (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
Thyroid Stimulating Hormone (TSH) | Serum | ±0,1 mU/L or 20% if > 0,5 mU/L | 5 RCPA | |
Tobramycin | Serum | ±20% | 1 CLIA, 3 CAP | |
Tobramycin | Serum | ±20% | 2 WSLH | |
Tobramycin | Serum | ±0,2 mg/L or 10% if > 2,0 mg/L | 5 RCPA | |
Transferrin | Serum | ±20% | 3 CAP | |
Transferrin | Serum | ±10% | 4 AAB | |
Transferrin | Serum | ±0,2 g/L or 8% if > 2,50 g/L | 5 RCPA | |
Triglycerides | Serum | ±15% | 1 CLIA, 2 WSLH, 3 CAP | |
Triglycerides | Body Fluids | ±25% | 2 WSLH | |
Triglycerides | Serum | ±25% | 4 AAB | |
Triglycerides | Serum | ±0,2 mmol/L or 12% if > 1,60 mmol/L | 5 RCPA | |
Triglycerides | Body Fluids | ±0,3 mmol/L or 25% if > 1,2 mmol/L | 5 RCPA | |
Troponin I | Serum | ±30% or 0,9 ng/mL (greater) | 1 CLIA, 2 WSLH | |
Troponin I | Serum | ±30% | 4 AAB | |
Troponin I | Serum | ±0,002 μg/L or 20% if > 0,010 μg/L | 5 RCPA | |
Troponin I | Serum | ±0,01 μg/L or 20% if > 0,05 μg/L | 5 RCPA | |
Troponin T | Serum | ±30% or 0,2 ng/mL (greater) | 1 CLIA, 2 WSLH | |
Troponin T | Serum | ±30% | 4 AAB | |
Troponin T | Serum | ±0,001 μg/L or 20% if > 0,050 μg/L | 5 RCPA | |
Troponin T | Serum | ±10 ng/L or 20% if > 50 ng/L | 5 RCPA | |
Tryptase | Serum | ±0,6 ug/L or 15% if > 4,0 ug/L | 5 RCPA | |
Urate | Serum | ±0,030 mmol/L or 8% if > 0,380 mmol/L | 5 RCPA | |
Urate | Body Fluids | ±0,06 mmol/L or 16% if > 0,38 mmol/L | 5 RCPA | |
Urate | Urine | ±0,3 mmol/L or 15% if > 2 mmol/L | 5 RCPA | |
Urea Nitrogen (BUN) | Serum | ±9% or 2 mg/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
Urea Nitrogen (BUN) | Urine | ±10% | 2 WSLH | |
Urea Nitrogen (BUN) | Serum | ±0,5 mmol/L or 12% if > 4,0 mmol/L | 5 RCPA | |
Urea Nitrogen (BUN) | Body Fluids | ±1,0 mmol/L or 24% if > 4,0 mmol/L | 5 RCPA | |
Urea Nitrogen (BUN) | Urine | ±20 mmol/L or 10% if > 200 mmol/L | 5 RCPA | |
Uric Acid | Serum | ±10% | 1 CLIA, 2 WSLH, 3 CAP | |
Uric Acid | Serum | ±17% | 4 AAB | |
Uric Acid | Urine | ±17% or 2 mg/dL | 2 WSLH | |
Valproate | Serum | ±4,0 mg/L or 10% if > 36,0 mg/L | 5 RCPA | |
Valproic Acid | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP | |
Valproic Acid | Serum | ±25% | 4 AAB | |
Valproic Acid, Free | Serum | ±3 SD or 10% (greater) | 3 CAP | |
Vanadium | Serum | ±1 nmol/L or 10% if > 10nmol/L | 5 RCPA | |
Vanadium | Urine | ±2 nmol/L or 10% if > 10nmol/L | 5 RCPA | |
Vancomycin | Serum | ±15% or 2 µg/mL (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
Vancomycin | Serum | ±25% or 1,0 μg/mL (greater) | 4 AAB | |
Vancomycin | Serum | ±2,0 mg/L or 10% if > 20,3 mg/L | 5 RCPA | |
Vitamin A | Serum | ±0,2 μmol/L or 12% if > 1,7 μmol/L | 5 RCPA | |
Vitamin B1 | Serum | ±9 nmol/L or 15% if > 60 nmol/L | 5 RCPA | |
Vitamin B2 | Serum | ±25 nmol/L or 10% if > 250 nmol/L | 5 RCPA | |
Vitamin B6 | Plasma, WB | ±9 nmol/L or 15% if > 60 nmol/L | 5 RCPA | |
Vitamin B12 | Serum | ±25% or 30 pg/mL (greater) | 1 CLIA, 2 WSLH | |
Vitamin B12 | Serum | ±25% | 4 AAB | |
Vitamin B12 | Serum | ±18 pmol/L or 15% if > 120 pmol/L | 5 RCPA | |
Vitamin C | Serum | ±7 μmol/L or 20% if > 35 μmol/L | 5 RCPA | |
Vitamin D3 | Serum | ±9 nmol/L or 15% if > 60 nmol/L | 5 RCPA | |
Vitamin E | Serum | ±3 μmol/L or 12% if > 25 μmol/L | 5 RCPA | |
von Willebrand Activity | Plasma | ±4% or 40% if > 10% | 5 RCPA | |
von Willebrand factor, Antigen (vWF:Ag) | Plasma | ±3% or 30% if > 10% | 5 RCPA | |
von Willebrand Collagen binding (vWF:CB) | Plasma | ±4% or 40% if > 10% | 5 RCPA | |
von Willebrand Ristocetin Cofactor (vWF:rCo) | Plasma | ±4% or 40% if > 10% | 5 RCPA | |
Voriconazole | Serum | ±0,2 mg/L or 10% if > 2,0 mg/L | 5 RCPA | |
WBC, White Cell Count, Leukocyte count) | WB | automated differential | ±10% | 1 CLIA, 2 WSLH |
WBC, White Cell Count, Leukocyte count) | WB | ±15% | 4 AAB | |
WBC, White Cell Count, Leukocyte count) | WB | ±0.5x109/L or 10% if > 5,0 x109/L | 5 RCPA | |
WBC Differential | WB | ±3SD based on the percentage of different types of white blood cells in the samples | 1 CLIA, 2 WSLH | |
WBC Differential | WB | automated differential | ±3% or 30% if > 10% | 5 RCPA |
Zinc | Serum, Urine | ±2 μmol/L or 10% if > 20,0 μmol/L | 5 RCPA | |
Zinc | WB | ±6 μmol/L or 10% if > 60 μmol/L | 5 RCPA |
Sources
Abbreviation | Source |
---|---|
1 CLIA | CLIA – Federal Register |
2 WLSH | Wisconsin State Laboratory of Hygiene |
3 CAP | College of American Pathologists |
4 AAB | American Association of Bioanalysts |
5 RCPA | The Royal College of Pathologists of Australasia and the Australasian Clinical Biochemist association Quality Assurance Program |
Total Allowable Error Table (Prior to 20 juin24)
Analyte | Discipline | Fluid | Method | Limit | Source |
---|---|---|---|---|---|
11-Deoxycortisol | Unclassified | 30 nmol/L, 15% | 7 RCPA | ||
11-Desoxycortisol | Unclassified | Serum | 27,10% | 5 BV | |
17-Hydroxyprogesterone | Unclassified | 3 nmol/L, 20% | 7 RCPA | ||
17-Hydroxyprogesterone | Unclassified | Serum | 30,20% | 5 BV | |
5HIAA | Unclassified | 20 umol/day, 20% | 7 RCPA | ||
5'-Hidroxiindolacetate - Concentration, 2 | Unclassified | Urine | 26,50% | 5 BV | |
5'Nucleotidase | Unclassified | Serum | 26,80% | 5 BV | |
A/C Ratio | Unclassified | 2,5 SD | 2 WSLH | ||
a1-Acid Glycoprotein | Unclassified | Serum | 16,20% | 5 BV | |
a1-Antichymotrypsin | Unclassified | Serum | 16,80% | 5 BV | |
a1-Antitrypsin | Unclassified | Serum | 9,20% | 5 BV | |
a1-Globulins | Unclassified | Serum | 15,70% | 5 BV | |
a1-Microglobulin - Concentration, first m | Unclassified | Urine | 43,90% | 5 BV | |
a2-Globulins | Unclassified | Serum | 12,60% | 5 BV | |
a2-Macroglobulin | Unclassified | Serum | 7,60% | 5 BV | |
a2-Microglobulin output, overnight | Unclassified | Urine | 34,70% | 5 BV | |
a-Amylase | Unclassified | Serum | 15,70% | 5 BV | |
a-Amylase (pancreatic) | Unclassified | Serum | 17,70% | 5 BV | |
a-Amylase concentration, random | Unclassified | Urine | 103,70% | 5 BV | |
Acetaminophen | Unclassified | Abbott AxSym | 3 SD | 4 CAP | |
Acetaminophen | Unclassified | 2,5 mg/mL or 25% | 6 AAB | ||
Acetaminophen | Unclassified | +/- 15% | 3 NYS | ||
Acetaminophen | Unclassified | 25% | 2 WSLH | ||
Acetaminophen | Unclassified | 20% | 8 CFX | ||
Acetone | Unclassified | 25% | 2 WSLH | ||
Acid Phosphatase | Unclassified | 1,5 U/L & ug/L, 15% | 7 RCPA | ||
Acid Phosphatase | Unclassified | Serum | 10,3 | 5 BV | |
Acid Phosphatase - Total | Unclassified | 1,5 U/L & ug/L, 15% | 7 RCPA | ||
Acid phosphatase tartrate resistent | Unclassified | Serum | 13,20% | 5 BV | |
ACTH | Unclassified | 2,0 pmol/L, 10% | 7 RCPA | ||
Activated Clotting Time | Unclassified | 20% | 6 AAB | ||
Activated Clotting Time (ACT) | Unclassified | 2 SD | 2 WSLH | ||
Activated Partial Thrombo Time | Unclassified | 15% | 6 AAB | ||
Activated Partial Thromboplastine Time | Unclassified | Plasma | 4,50% | 5 BV | |
Active Renin | Unclassified | 1,0 uU/mL, 25% | 7 RCPA | ||
Adenosine Deaminase | Unclassified | Serum | 16,70% | 5 BV | |
Adrenaline | Unclassified | 50 nmol/day, 33% | 7 RCPA | ||
AFP | Unclassified | 5 kIU/L, 20% | 7 RCPA | ||
AFP | Unclassified | Centaur | 3 SD | 4 CAP | |
AFP | Unclassified | Amniotic Fluid | +/- 3 SD | 3 NYS | |
AFP | Unclassified | Maternal Sera | +/- 3 SD | 3 NYS | |
AFP | Unclassified | Amniotic Fluid | Centaur | 3 SD | 4 CAP |
AFPTM | Unclassified | +/- 3 SD | 3 NYS | ||
AFP-Tumor (Chiron) | Unclassified | Centaur | 3 SD | 4 CAP | |
Alanine Aminotransferase | Unclassified | 35% | 8 CFX | ||
Alanine Aminotransferase | Unclassified | 20% | 6 AAB | ||
Alanine Aminotransferase | Unclassified | Serum | 32,10% | 5 BV | |
Alanine Aminotransferase | Chimie | +/- 20% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Alanine Aminotransferase | Unclassified | 8 U/L, 15% | 7 RCPA | ||
Alanine Aminotransferase | Unclassified | AU640 | 20% | 4 CAP | |
Alanine Transaminase | Unclassified | 8 U/L, 15% | 7 RCPA | ||
Alanine Transaminase | Unclassified | AU640 | 20% | 4 CAP | |
Albumin | Chimie | +/- 10% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Albumin | Chimie | AU640 | 10% | 4 CAP | |
Albumin | Chimie | 10% | 8 CFX | ||
Albumin | Chimie | Serum | 3,90% | 5 BV | |
Albumin | Chimie | 2,0 g/L, 10% | 7 RCPA | ||
Albumin | Unclassified | Cerebrospinal Fluid | BNII | 20% | 4 CAP |
Albumin | Unclassified | Cerebrospinal Fluid | 0,10 g/L, 10% | 7 RCPA | |
Albumin | Unclassified | Urine | 0,1 g/L, 10% | 7 RCPA | |
Albumin | Unclassified | Blood | BNII | 20% | 4 CAP |
Albumin - Concentration, first morning | Unclassified | Urine | 46,10% | 5 BV | |
Alcohol | Toxicologie | Blood | +/- 25% | 1 CLIA, 2 WSLH, 6 AAB | |
Alcohol | Unclassified | 2,2 mmol/L, 10% | 7 RCPA | ||
Alcohol | Unclassified | Blood | +/- 10% | 3 NYS | |
Alcohol (Ethanol) | Unclassified | Urine | Pos/Neg | 2 WSLH | |
Alcohol | Unclassified | Serum | 25% | 6 AAB | |
Aldosterone | Unclassified | 75,0 pmol/L, 15% | 7 RCPA | ||
Aldosterone | Unclassified | Serum | 36,70% | 5 BV | |
Aldosterone - Concentration | Unclassified | Urine | 39,60% | 5 BV | |
Alkaline Phosphatase | Unclassified | AU640 | 30% | 4 CAP | |
Alkaline Phosphatase | Chimie | +/- 30% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Alkaline Phosphatase | Chimie | Serum | 11,70% | 5 BV | |
Alkaline Phosphatase | Unclassified | 15 U/L, 15% | 7 RCPA | ||
Alkaline Phosphatase | Unclassified | 30% | 6 AAB | ||
Alkaline Phosphatase | Unclassified | 30% | 8 CFX | ||
Alkaline phosphatase, bone isoform | Unclassified | Serum | 14,50% | 5 BV | |
Alpha 1 Antitrypsin | Unclassified | BNII | 3 SD | 4 CAP | |
Alpha 1 Antitrypsin | Immunology | +/- 3 SD | 1 CLIA, 3 NYS, 6 AAB | ||
Alpha 1 Antitrypsin | Unclassified | 3SD | 6 AAB | ||
Alpha fetoprotein (Prenatal screen) | Unclassified | 3 SD | 2 WSLH | ||
Alpha-fetoprotein | Immunology | 5 kIU/L, 20% | 7 RCPA | ||
Alpha-fetoprotein | Immunology | +/- 3 SD | 1 CLIA, 2 WSLH | ||
Amikacin | Unclassified | 2,0 mg/L, 10% | 7 RCPA | ||
Amikacin | Unclassified | 25% | 2 WSLH | ||
Amikacin | Unclassified | 15% | 8 CFX | ||
Amiodarone | Unclassified | 0,2 umol/L, 10% | 7 RCPA | ||
Amitriptyline | Unclassified | 10 umol/L, 10% | 7 RCPA | ||
Amitriptyline | Unclassified | 15% | 8 CFX | ||
Ammonia | Unclassified | AU640 | not evaluated | 4 CAP | |
Ammonia | Unclassified | 3 umol/L, 10% | 7 RCPA | ||
Ammonia | Unclassified | 2,5 SD | 2 WSLH | ||
Ammonia | Unclassified | Serum | 10 umol/L or 5% | 6 AAB | |
Ammonia - Output | Unclassified | Urine | 29,60% | 5 BV | |
Amphetamines | Unclassified | Abbott AxSym | 80% consensus | 4 CAP | |
Amphetamines | Unclassified | Pos/Neg | 2 WSLH | ||
Amphetamines | Unclassified | 20% or 2 SD | 3 NYS | ||
Amphetamines - Qualitative | Unclassified | Presence or Absence | 3 NYS | ||
Amylase | Chimie | 15 U/L, 15% | 7 RCPA | ||
Amylase | Chimie | +/- 30% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Amylase | Chimie | AU640 | 30% | 4 CAP | |
Amylase | Chimie | 20% | 8 CFX | ||
Amylase | Unclassified | Urine | 30% | 2 WSLH | |
Amylase | Unclassified | Urine | AU640 | 3 SD | 4 CAP |
Androstenedione | Unclassified | Serum | 22,60% | 5 BV | |
Androstenedione | Unclassified | 2,0 nmol/L | 7 RCPA | ||
Angiotensin converting enzyme | Unclassified | Plasma | 17,90% | 5 BV | |
Anti-CMV | Unclassified | Positive or Negative | 3 NYS | ||
Anti-Human Immunodeficiency virus | Immunology | Reaction or nonreactive | 1 CLIA | ||
Antinuclear antibody | Immunology | Target value +/- 2 dilution or (pos. or neg.) | 1 CLIA, 3 NYS | ||
Antistreptolysin O | Immunology | Target value +/- 2 dilution or (pos. or neg.) | 1 CLIA, 3 NYS | ||
Antithrombin III | Unclassified | Plasma | 8,30% | 5 BV | |
Apolipoprotein A1 | Unclassified | BNII | 3 SD | 4 CAP | |
Apolipoprotein A1 | Unclassified | 25 mg/dL or 30% | 6 AAB | ||
Apolipoprotein A1 | Unclassified | 0,2 g/L, 10% | 7 RCPA | ||
Apolipoprotein A1 | Unclassified | Serum | 9,10% | 5 BV | |
Apolipoprotein A1 | Unclassified | 10% | 8 CFX | ||
Apolipoprotein B | Unclassified | BNII | 3 SD | 4 CAP | |
Apolipoprotein B | Unclassified | 20 mg/dL or 25% | 6 AAB | ||
Apolipoprotein B | Unclassified | 0,2 g/L, 10% | 7 RCPA | ||
Apolipoprotein B | Unclassified | 12% | 8 CFX | ||
Apolipoprotein B | Unclassified | Serum | 11,60% | 5 BV | |
Apolipoprotein B100 | Unclassified | BNII | not evaluated | 4 CAP | |
Ascorbic Acid | Unclassified | Serum | 29,90% | 5 BV | |
Aso-Antistreptolysin | Unclassified | BNII | 2 SD | 4 CAP | |
Aspartate Aminotransferase | Unclassified | 20% | 6 AAB | ||
Aspartate Aminotransferase | Unclassified | 20% | 8 CFX | ||
Aspartate Aminotransferase | Unclassified | Serum | 15,20% | 5 BV | |
Aspartate Aminotransferase | Chimie | +/- 20% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
a-Tocopherol | Unclassified | Serum | 16,20% | 5 BV | |
Automated Differential | Unclassified | 3SD | 6 AAB | ||
b2-Microglobulin | Unclassified | Serum | 9% | 5 BV | |
Barbiturates | Unclassified | 20% or 2 SD | 3 NYS | ||
Barbiturates | Unclassified | Abbott AxSym | 80% consensus | 4 CAP | |
Barbiturates | Unclassified | Pos/Neg | 2 WSLH | ||
Basophile, count | Unclassified | Serum | 38,50% | 5 BV | |
b-Carotene | Unclassified | Serum | 43% | 5 BV | |
Benzodiazepine | Unclassified | Abbott AxSym | 80% consensus | 4 CAP | |
Benzodiazepine | Unclassified | 20% or 2 SD | 3 NYS | ||
Benzodiazepine | Unclassified | Pos/Neg | 2 WSLH | ||
Benzoylecgonine | Unclassified | 20% or 2 SD | 3 NYS | ||
Beta 2 microglobulin | Unclassified | 0,06 mg/L or 30% | 6 AAB | ||
Beta Carotene | Unclassified | 0,2 umol/L, 10% | 7 RCPA | ||
Beta-2 Microglobulin | Unclassified | 0,2 mg/L, 10% | 7 RCPA | ||
Beta-Hydroxybutyric Acid | Unclassified | 2 SD | 8 CFX | ||
b-Globulins | Unclassified | Serum | 11,70% | 5 BV | |
Bicarbonate | Unclassified | 2,0 mmol/L, 10% | 7 RCPA | ||
Bicarbonate (Total CO2) | Unclassified | 4 mEq/L or 20% | 6 AAB | ||
Bilirubin - Direct | Unclassified | 50% | 8 CFX | ||
Bilirubin - Direct | Unclassified | AU640 | 20% or 0,4 mg/dL (greater) | 4 CAP | |
Bilirubin - Direct | Unclassified | 0,4 mg/dL or 20% | 2 WSLH | ||
Bilirubin - Neonatal | Unclassified | 31% | 8 CFX | ||
Bilirubin - Total | Unclassified | 5 umol/L, 10% | 7 RCPA | ||
Bilirubin - Total | Unclassified | 31% | 8 CFX | ||
Bilirubin - Total | Unclassified | Serum | 31,10% | 5 BV | |
Bilirubin - Total | Chimie | +/- 0,4 mg/dL or +/- 20% (greater) | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Bilirubin - Total | Unclassified | AU640 | 20% or 0,4 mg/dL (greater) | 4 CAP | |
Bilirubin - Total | Unclassified | 0,4 mg/dL or 20% | 6 AAB | ||
Bilirubin - Conjugated | Unclassified | 10 umol/L, 20% | 7 RCPA | ||
Bilirubin - Conjugated | Unclassified | Serum | 44,50% | 5 BV | |
Bilirubin - Qualitative | Unclassified | Urine | 80% Agreement | 3 NYS | |
Bilirubin - Neonatal | Unclassified | 0,4 mg/dL or 20% | 2 WSLH | ||
Blood gas p02 | Chimie | +/- 3 SD | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Blood gas pCO2 | Chimie | +/- 5 mm Hg or +/- 8% (greater) | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Blood gas pH | Chimie | +/- 0,04 | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
BNP | Unclassified | Centaur | not evaluated | 4 CAP | |
BNP | Unclassified | 5,0 pg/mL or 20% | 6 AAB | ||
BNP | Unclassified | 2,0 SD | 2 WSLH | ||
BPb | Unclassified | +/-4 µg/dL (values <40µg/dL) or +/-10% (values >40µg/dL) | 3 NYS | ||
Bright CD45-/CD14+ | Unclassified | 3 SD | 2 WSLH | ||
C Peptide | Unclassified | 1,0 nmol/L, 10% | 7 RCPA | ||
C Peptide | Unclassified | Serum | 11,70% | 5 BV | |
C3 Complement | Unclassified | BNII | 3 SD | 4 CAP | |
C3 Complement | Unclassified | Serum | 8,40% | 5 BV | |
C4 Complement | Unclassified | BNII | 3 SD | 4 CAP | |
C4 Complement | Unclassified | Serum | 16% | 5 BV | |
CA 125 | Unclassified | 2 SD | 2 WSLH | ||
CA 125 | Unclassified | 20 kU/L, 20% | 7 RCPA | ||
CA 125 | Unclassified | +/- 3 SD | 3 NYS | ||
CA 125 | Unclassified | 9 U/mL or 30% | 6 AAB | ||
CA 125 Antigen | Unclassified | Serum | 38,20% | 5 BV | |
CA 15-3 | Unclassified | 2 SD | 2 WSLH | ||
CA 15-3 Antigen | Unclassified | Serum | 15,50% | 5 BV | |
CA 19-9 | Unclassified | 2 SD | 2 WSLH | ||
CA 19-9 Antigen | Unclassified | Serum | 44,30% | 5 BV | |
CA 549 antigen | Unclassified | Serum | 16,20% | 5 BV | |
CA15-3 | Unclassified | 3 kU/L, 15% | 7 RCPA | ||
CA15-3 | Unclassified | +/- 3 SD | 3 NYS | ||
CA19-9 | Unclassified | 3 kU/L, 15% | 7 RCPA | ||
CA19-9 | Unclassified | +/- 3 SD | 3 NYS | ||
CA27.29 | Unclassified | +/- 3 SD | 3 NYS | ||
Caffeine | Unclassified | 15% | 8 CFX | ||
Calcitonin | Unclassified | 2 ng/L, 10% | 7 RCPA | ||
Calcium | Unclassified | Urine | 1,0 mg/dL | 6 AAB | |
Calcium | Unclassified | 1,0 mg/dL | 6 AAB | ||
Calcium | Unclassified | AU640 | 1 mg/dL | 4 CAP | |
Calcium | Unclassified | 0,10 mmol/L | 7 RCPA | ||
Calcium | Unclassified | 8% | 8 CFX | ||
Calcium | Unclassified | Serum | 2,40% | 5 BV | |
Calcium | unclassified | Urine | 1 mg/dL | 2 WSLH | |
Calcium | Unclassified | Urine | AU640 | 31% | 4 CAP |
Calcium | Unclassified | Urine | 0,20 mmol/L | 7 RCPA | |
Calcium - Ionized | Unclassified | 10% | 8 CFX | ||
Calcium - Ionized | Unclassified | Radiometer 725 | 3 SD | 4 CAP | |
Calcium - Ionized | Unclassified | Urine | 2,10% | 5 BV | |
Calcium - Concentration, 24h | Unclassified | Urine | 34,10% | 5 BV | |
Calcium - Output, 24h | Unclassified | Urine | 31% | 5 BV | |
Calcium - Total | Chimie | +/- 1,0 mg/dL | 1 CLIA | ||
Cannabinoid | Unclassified | Abbott AxSym | 80% consensus | 4 CAP | |
Cannabinoid | Unclassified | Pos/Neg | 2 WSLH | ||
Carbamazepine | Toxicologie | 2,0 umol/L, 10% | 7 RCPA | ||
Carbamazepine | Toxicologie | +/- 25% | 1 CLIA, 2 WSLH, 6 AAB | ||
Carbamazepine | Toxicologie | +/- 15% | 3 NYS | ||
Carbamazepine | Toxicologie | Abbott AxSym | 25% | 4 CAP | |
Carbamazepine | Toxicologie | 25% | 8 CFX | ||
Carbamazepine, free | Unclassified | TDX | 3 SD | 4 CAP | |
Carbohydrate deficient transferrin | Unclassified | Serum | 15,70% | 5 BV | |
Carbon Dioxide | Unclassified | 5,0 mmol/L | 2 WSLH | ||
Carboxyhemoglobin | Unclassified | 3 SD | 2 WSLH | ||
Carboxyhemoglobin | Unclassified | Radiometer 725 | 3 SD | 4 CAP | |
Carcinoembryonic Antigen | Unclassified | 1,2 ng/mL or 30% | 6 AAB | ||
Carcinoembryonic Antigen | Unclassified | Serum | 21,80% | 5 BV | |
CD19+ | Unclassified | 3 SD | 2 WSLH | ||
CD2+ | Unclassified | 3 SD | 2 WSLH | ||
CD20+ | Unclassified | 3 SD | 2 WSLH | ||
CD3-/CD16+56+ | Unclassified | 3 SD | 2 WSLH | ||
CD3+ | Unclassified | 3 SD | 2 WSLH | ||
CD3+/CD4+ | Unclassified | 3 SD | 2 WSLH | ||
CD3+/CD8+ | Unclassified | 3 SD | 2 WSLH | ||
CD4+ | Unclassified | 3 SD | 2 WSLH | ||
CD5+ | Unclassified | 3 SD | 2 WSLH | ||
CD8+ | Unclassified | 3 SD | 2 WSLH | ||
CEA | Unclassified | Abbott AxSym | 3 SD | 4 CAP | |
CEA | Unclassified | 2,0 ug/L, 20% | 7 RCPA | ||
CEA | Unclassified | 1,2 ng/mL or 30% | 2 WSLH | ||
CEA | Unclassified | +/- 3 SD | 3 NYS | ||
Cell Identification | Hématologie | 90% or greater consensus on identification | 1 CLIA, 3 NYS | ||
Ceruloplasmin | Unclassified | BNII | 3 SD | 4 CAP | |
Ceruloplasmin | Unclassified | Serum | 7,80% | 5 BV | |
Chloride | Chimie | 3,0 mmol/L | 7 RCPA | ||
Chloride | Chimie | +/- 5% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Chloride | Chimie | Radiometer 725 | 5% | 4 CAP | |
Chloride | Chimie | AU640 | 5% | 4 CAP | |
Chloride | Chimie | 5% | 8 CFX | ||
Chloride | Chimie | Serum | 1,50% | 5 BV | |
Chloride | Unclassified | Urine | 5% | 2 WSLH | |
Chloride | Unclassified | Urine | AU640 | 3 SD | 4 CAP |
Chloride | Unclassified | Sweat | 2 mmol/L, 10% | 7 RCPA | |
Chloride | Unclassified | Urine | 2,0 mmol/L, 10% | 7 RCPA | |
Cholesterol | Unclassified | 0,50 mmol/L, 5% | 7 RCPA | ||
Cholesterol | Unclassified | AU640 | 10% | 4 CAP | |
Cholesterol | Unclassified | Serum | 9% | 5 BV | |
Cholesterol - HDL | Unclassified | 11% | 8 CFX | ||
Cholesterol - HDL | Chimie | +/- 30% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Cholesterol - HDL | Unclassified | ||||
Cholesterol - HDL | Unclassified | 0,20 mmol/L, 10% | 7 RCPA | ||
Cholesterol - HDL | Unclassified | 30% | 6 AAB | ||
Cholesterol - HDL | Unclassified | Serum | 11,10% | 5 BV | |
Cholesterol - HDL | Unclassified | AU640 | 30% | 4 CAP | |
Cholesterol - LDL | Unclassified | 15% | 8 CFX | ||
Cholesterol - LDL | Unclassified | Non-graded analyte | 3 NYS | ||
Cholesterol - LDL | Unclassified | 30% | 2 WSLH | ||
Cholesterol - Total | Unclassified | 9% | 8 CFX | ||
Cholesterol - Total | Unclassified | 10% | 6 AAB | ||
Cholesterol - Total | Chimie | +/- 10% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Cholinesterase | Unclassified | Serum | 8,90% | 5 BV | |
Cholinesterase, catalitic activity | Unclassified | Serum | 7,40% | 5 BV | |
CK2 Isoenzyme (CKMB) | Unclassified | 3SD | 6 AAB | ||
CO2 | Unclassified | AU640 | 3 SD | 4 CAP | |
CO2 - Total | Unclassified | 20% | 8 CFX | ||
Cocaine-Metabolite | Unclassified | Pos/Neg | 2 WSLH | ||
Cocaine-Metabolite | Unclassified | Abbott AxSym | 80% consensus | 4 CAP | |
Complement C3 | Immunology | +/- 3 SD | 1 CLIA, 3 NYS, 6 AAB | ||
Complement C4 | Immunology | +/- 3 SD | 1 CLIA, 3 NYS, 6 AAB | ||
Conjugated Bilirubin, Neonatal | Unclassified | 10 umol/L, 20% | 7 RCPA | ||
Copper | Unclassified | Plasma | 11,80% | 5 BV | |
Copper | Unclassified | Serum | 7,70% | 5 BV | |
Cortisol | Endocrinology | 30 nmol/L, 15% | 7 RCPA | ||
Cortisol | Endocrinology | +/- 25% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Cortisol | Endocrinology | 30% | 8 CFX | ||
Cortisol | Endocrinology | Serum | 29,80% | 5 BV | |
Cortisol | Endocrinology | Centaur | 25% | 4 CAP | |
C-Propeptide type I procollagen | Unclassified | Serum | 11,60% | 5 BV | |
cPSA | Unclassified | +/- 3 SD | 3 NYS | ||
C-Reactive protein | Unclassified | Serum | 68,30% | 5 BV | |
Creatine Kinase | Chimie | +/- 30% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Creatine Kinase | Chimie | Serum | 30,30% | 5 BV | |
Creatine Kinase | Unclassified | 15 U/L, 15% | 7 RCPA | ||
Creatine Kinase | Unclassified | 30% | 6 AAB | ||
Creatine Kinase | Unclassified | 30% | 8 CFX | ||
Creatine Kinase isoenzymes | Chimie | MB elevated (present or absent) or Target value +/- 3 SD | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Creatine Kinase MB | Unclassified | 6 U/L & ug/L, 15% | 7 RCPA | ||
Creatine Kinase MB | Unclassified | Centaur | 3 SD | 4 CAP | |
Creatine Kinase MB, % | Unclassified | Serum | 16,50% | 5 BV | |
Creatine Kinase MB, activity | Unclassified | 40% | 8 CFX | ||
Creatine Kinase MB, activity | Unclassified | Serum | 24,10% | 5 BV | |
Creatine Kinase MB, mass | Unclassified | 2 SD | 8 CFX | ||
Creatine Kinase MB, mass | Unclassified | Serum | 31,20% | 5 BV | |
Creatine Kinase MB, qualitative | Unclassified | Pos/Neg | 2 WSLH | ||
Creatine Kinase, Total | Unclassified | AU640 | 30% | 4 CAP | |
Creatinine | Chimie | AU640 | 15% or 0,3 mg/dL (greater) | 4 CAP | |
Creatinine | Chimie | 0,01 mmol/L, 10% | 7 RCPA | ||
Creatinine | Chimie | +/- 0,3 mg/dL or +/- 15% (greater) | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Creatinine | Chimie | 25% | 8 CFX | ||
Creatinine | Chimie | Serum | 6,90% | 5 BV | |
Creatinine | Unclassified | Urine | AU640 | 17% | 4 CAP |
Creatinine | Unclassified | Urine | 0,5 mmol/L, 10% | 7 RCPA | |
Creatinine | Unclassified | Urine | 3 mg/dL or 15% | 6 AAB | |
Creatinine - Quantitative | Unclassified | Urine | 0,3 mg/dL or 17% | 2 WSLH | |
Creatinine - Semi Quantitative | Unclassified | Urine | 2 WSLH | ||
Creatinine Clearence | Unclassified | Patient- | 16% | 5 BV | |
Creatinine - Concentration | Unclassified | Urine | 28,40% | 5 BV | |
Creatinine - Output | Unclassified | Urine | 15,40% | 5 BV | |
CRP | Unclassified | BNII | 2 SD | 4 CAP | |
CRP | Unclassified | 0,4 mg/dL or 3 SD% | 6 AAB | ||
Cryptococcus neoformans Antigen | Unclassified | Positive or Negative or +/- 2 dilutions | 3 NYS | ||
CSF Protein | Unclassified | AU640 | 2 SD | 4 CAP | |
C-Telopeptide type I procollagen | Unclassified | Serum | 14,10% | 5 BV | |
Cyclosporine | Unclassified | TDX | 3 SD | 4 CAP | |
Cystein | unclassified | Plasma | 8,30% | 5 BV | |
d-Dimer | Unclassified | 30% | 6 AAB | ||
d-Dimer - Interpretation | Unclassified | Pos/Neg | 2 WSLH | ||
d-Dimer - Quantitative | Unclassified | 2 SD | 2 WSLH | ||
d-Dimer - Semi Quantitative | unclassified | Pos/Neg | 2 WSLH | ||
Dehydroepiandrosterone sulfate | Unclassified | Serum | 22,20% | 5 BV | |
Deoxipyridinoline/creatinine, 24h | Unclassified | Urine | 21,20% | 5 BV | |
Deoxipyridinoline/creatinine, morning sp | Unclassified | Urine | 33% | 5 BV | |
Desipramine | Unclassified | 15% | 8 CFX | ||
DHEA Sulfate | Unclassified | 2,5 SD | 2 WSLH | ||
DHEA Sulphate | Unclassified | 2 SD | 8 CFX | ||
DHEA Sulphate | Unclassified | 1,0 umol/L, 10% | 7 RCPA | ||
Digoxin | Toxicologie | Centaur | 20% or 0,2 ng/mL (greater) | 4 CAP | |
Digoxin | Toxicologie | 15% or 0,2 ng/mL | 3 NYS | ||
Digoxin | Toxicologie | 0,2 nmol/L, 10% | 7 RCPA | ||
Digoxin | Toxicologie | +/- 20% or 0,2 ng/mL (greater) | 1 CLIA, 2 WSLH, 6 AAB | ||
Digoxin | Toxicologie | 25% | 8 CFX | ||
Dipeptidyl-peptidase IV | Unclassified | Plasma | 10,90% | 5 BV | |
Direct Bilirubin | Unclassified | 0,4 mg/dL or 20% | 6 AAB | ||
Disopyramide | Unclassified | 2,0 umol/L, 10% | 7 RCPA | ||
Disopyramide | Unclassified | 15% | 8 CFX | ||
DMF | Unclassified | 0,45 mmol/L or 30% | 6 AAB | ||
Dopamine | Unclassified | 0,25 umol/day, 25% | 7 RCPA | ||
DPD - Free | Unclassified | Urine | 15 nmol/L, 15% | 7 RCPA | |
DPD - Total | Unclassified | Urine | 15 nmol/L, 15% | 7 RCPA | |
Elastase-Pl | Unclassified | Plasma | 16,50% | 5 BV | |
Eosinophils, count | Unclassified | Blood | 37,10% | 5 BV | |
EP | Unclassified | +/-6 µg/dL (values <40µg/dL) or +/-15% (values >40µg/dL) | 3 NYS | ||
Erythrocites, count | Unclassified | Blood | 4,40% | 5 BV | |
Erythrocites, count | Hématologie | +/- 6% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Erythrocyte Sedimentation Rate (ESR) | Unclassified | 3SD | 6 AAB | ||
Erythrocyte Sedimentation Rate (ESR) - Rapid | Unclassified | 3SD | 6 AAB | ||
Erythrocytes | Unclassified | 6% | 6 AAB | ||
Estradiol | Unclassified | 3 pg/mL or 30% | 6 AAB | ||
Estradiol | Unclassified | 3 ng/mL or 30% | 2 WSLH | ||
Estradiol | Unclassified | 2 SD | 8 CFX | ||
Estradiol | Unclassified | +/-25% or 30 pg/mL | 3 NYS | ||
Estradiol | Unclassified | Urine | 27% | 5 BV | |
Estriol | Unclassified | 2,5 SD | 2 WSLH | ||
Estriol - Total | Unclassified | 2 SD | 8 CFX | ||
Estriol - Unconjugated | Unclassified | 2 SD | 8 CFX | ||
Estrogen | Unclassified | 2,5 SD | 2 WSLH | ||
Ethanol | Unclassified | Abbott AxSym | 80% consensus | 4 CAP | |
Ethanol | Unclassified | Urine | HP GLC | 25% or 9 mg/dL (greater) | 4 CAP |
Ethanol | unclassified | 20% or 2 SD | 3 NYS | ||
Ethanol | Unclassified | Blood | HP GLC | 25% | 4 CAP |
Ethanol | Unclassified | 15% | 8 CFX | ||
Ethosuximide | Toxicologie | 3 umol/L, 10% | 7 RCPA | ||
Ethosuximide | Toxicologie | +/- 20% | 1 CLIA, 2 WSLH | ||
Ethosuximide | Toxicologie | +/- 15% | 3 NYS | ||
Ethosuximide | Toxicologie | 15% | 8 CFX | ||
Factor VII coagulation | Unclassified | Plasma | 0,107 | 5 BV | |
Factor VIII coagulation | Unclassified | Plasma | 0,089 | 5 BV | |
Faecal Percent Dry Weight | Unclassified | 1, 10% | 7 RCPA | ||
Faecal Total Porphyrin | Unclassified | 15 umol/kg, 15% | 7 RCPA | ||
Fentanyl | Unclassified | 20% or 2 SD | 3 NYS | ||
Ferritin | Unclassified | 6,0 ug/L, 15% | 7 RCPA | ||
Ferritin | unclassified | 4,5 ng/mL or 30% | 2 WSLH | ||
Ferritin | Unclassified | 4,5 ng/mL or 30% | 6 AAB | ||
Ferritin | Unclassified | Centaur | 3 SD | 4 CAP | |
Ferritin | Unclassified | 19,30% | 8 CFX | ||
Ferritine | unclassified | Serum | 17,30% | 5 BV | |
Fibrinogen | Hématologie | +/- 20% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Fibrinogen | Hématologie | Plasma | 13,60% | 5 BV | |
Folate | Unclassified | Serum | Centaur | 3 SD | 4 CAP |
Folate | Unclassified | 2 SD | 8 CFX | ||
Folate | Unclassified | 1,0 umol/day, 30% | 7 RCPA | ||
Folate | Unclassified | 0,9 ng/mL or 30% | 2 WSLH | ||
Folate | Unclassified | 0,9 ng/mL or 30% | 6 AAB | ||
Folate | Unclassified | Serum | 39% | 5 BV | |
Folate | Unclassified | Blood-Erythrocytes | 26,70% | 5 BV | |
Folic Acid | Unclassified | +/- 30% or 2,0 ng/mL | 3 NYS | ||
Follicle Stimulating Hormone (FSH) | Unclassified | 2 SD | 8 CFX | ||
Follicle Stimulating Hormone (FSH) | Unclassified | Serum | 16,70% | 5 BV | |
Follicle Stimulating Hormone (FSH) | Unclassified | 2 mIU/mL or 25% | 6 AAB | ||
fPSA | Unclassified | +/- 3 SD | 3 NYS | ||
Fractional Carboxyhemoglobin | Unclassified | 0,02 | 7 RCPA | ||
Fractional Methemoglobin | Unclassified | 1,0, 10% | 7 RCPA | ||
Fractional Oxyhemoglobin | Unclassified | 3, 4% | 7 RCPA | ||
Free Estriol | Unclassified | +/-25% or 3,0 ng/mL | 3 NYS | ||
Free phenytoin | Unclassified | +/- 20% | 3 NYS | ||
Free PSA | Unclassified | 1,5 ug/L, 15% | 7 RCPA | ||
Free T3 | Unclassified | 3,0 pmol/L | 7 RCPA | ||
Free T3 | Unclassified | 3 SD | 2 WSLH | ||
Free T4 (Endocrinology) | Endocrinology | 1,5 pmol/L, 15% | 7 RCPA | ||
Free T4 (General Chemistry) | Chimie | 3 pmol/L, 15% | 7 RCPA | ||
Free thyroxine | Endocrinology | +/- 3 SD | 1 CLIA, 2 WSLH, 3 NYS | ||
Free thyroxine (FT4) | Unclassified | Serum | 9,90% | 5 BV | |
Fructosamine | Unclassified | 30 umol/L, 10% | 7 RCPA | ||
Fructosamine | Unclassified | Serum | 4,50% | 5 BV | |
Follicle Stimulating Hormone (FSH) | Unclassified | 4,0 IU/L, 20% | 7 RCPA | ||
Follicle Stimulating Hormone (FSH) | Unclassified | Centaur | 3 SD | 4 CAP | |
Follicle Stimulating Hormone (FSH) | Unclassified | 2 mIU/mL or 25% | 2 WSLH | ||
Follicle Stimulating Hormone (FSH) | Unclassified | +/-25% | 3 NYS | ||
Galactosy hydroxylisine | Unclassified | Serum | 16,80% | 5 BV | |
Gamma-Glutamyl Transferase | Unclassified | +/- 30% | 3 NYS | ||
Gamma-Glutamyl Transferase | Unclassified | 20% | 2 WSLH | ||
Gamma-Glutamyl Transferase | Unclassified | 30% | 8 CFX | ||
Gamma-Glutamyl Transferase | unclassified | 10 IU/L or 20% | 6 AAB | ||
Gamma-Glutamyl Transferase | Unclassified | Serum | 22,20% | 5 BV | |
Gamma-Glutamyl Transferase | Unclassified | 8 U/L, 15% | 7 RCPA | ||
Gamma-Glutamyl Transferase | Unclassified | AU640 | 3 SD | 4 CAP | |
Gastrin | Unclassified | 25 pmol/L, 10% | 7 RCPA | ||
Gentamicin | Toxicologie | 0,5 mg/L, 10% | 7 RCPA | ||
Gentamicin | Toxicologie | +/- 25% | 1 CLIA, 2 WSLH, 6 AAB | ||
Gentamicin | Toxicologie | +/- 15% | 3 NYS | ||
Gentamicin | Toxicologie | Abbott AxSym | 25% | 4 CAP | |
Gentamicin | Toxicologie | 20% | 8 CFX | ||
g-Globulins | Unclassified | Serum | 16,80% | 5 BV | |
Globulins, total | Unclassified | Serum | 8% | 5 BV | |
Glucose | Chimie | Radiometer 725 | 10% or 6 mg/dL (greater) | 4 CAP | |
Glucose | Chimie | AU640 | 10% or 6 mg/dL (greater) | 4 CAP | |
Glucose | Chimie | 0,5 mmol/L, 10% | 7 RCPA | ||
Glucose | Chimie | +/- 6 mg/dL or +/- 10% (greater) | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Glucose | Chimie | Serum | 6,30% | 5 BV | |
Glucose | Unclassified | Urine | 10% | 2 WSLH | |
Glucose | Unclassified | Cerebrospinal Fluid | 10% | 2 WSLH | |
Glucose | Unclassified | Whole Blood | 20 mg/dL or 20% | 2 WSLH | |
Glucose | Unclassified | Gazométrie sanguine | 1,0 mmol/day, 10% | 7 RCPA | |
Glucose | Unclassified | Cerebrospinal Fluid | 1,0 mmol/L, 10% | 7 RCPA | |
Glucose | Unclassified | Urine | 1,0 mmol/L, 10% | 7 RCPA | |
Glucose | Unclassified | Urine | AU640 | 10% or 6 g/24 hs (greater) | 4 CAP |
Glucose | Unclassified | 0,3 mmol/L, 8,0% | 8 CFX | ||
Glucose | Unclassified | Whole Blood | 6 mg/dL or 10% | 6 AAB | |
Glucose - Qualitative | Unclassified | Urine | 80% Agreement | 3 NYS | |
Glucose-6-phosphate-1-dehydrogenase | Unclassified | Blood-Erythrocytes | 38,50% | 5 BV | |
Glutathione Peroxidase | Unclassified | Serum | 11,70% | 5 BV | |
Glycated Albumin | Unclassified | Serum | 7,20% | 5 BV | |
Glycated Hemoglobin A1c | Unclassified | 9% | 8 CFX | ||
Glycated total protein | Unclassified | Serum | 3,70% | 5 BV | |
Glycohemoglobin | Unclassified | 1,00% or 25% | 6 AAB | ||
Growth Hormone | Unclassified | 2 mU/L, 20% | 7 RCPA | ||
Haptoglobin | Unclassified | BNII | not evaluated | 4 CAP | |
Haptoglobin | Unclassified | Plasma or Serum | 27,30% | 5 BV | |
hCG | Unclassified | 32% | 8 CFX | ||
hCG | Unclassified | Maternal Sera | +/- 3 SD | 3 NYS | |
hCG - Quantitative | Unclassified | Centaur | 3 SD | 4 CAP | |
hCG - Qualitative | Unclassified | Serum | Pos/Neg | 2 WSLH | |
hCG - Quantitative | Unclassified | 3,0 IU/L, 15% | 7 RCPA | ||
hCG - Quantitative | Unclassified | Urine | 5 IU/L, 10% | 7 RCPA | |
HDL 1 cholesterol | Unclassified | Serum | 11,50% | 5 BV | |
HDL 2 cholesterol | Unclassified | Serum | 23,90% | 5 BV | |
HDL 3 cholesterol | Unclassified | Serum | 9,80% | 5 BV | |
Hematocrit | Hématologie | +/- 6% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Hematocrit | Hématologie | Blood | 4,10% | 5 BV | |
Hemoglobin | Hématologie | +/- 7% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Hemoglobin | Hématologie | Blood | 4,10% | 5 BV | |
Hemoglobin A1c | Unclassified | Serum | 4,40% | 5 BV | |
Hemoglobin A1c | Unclassified | 1,0 or 25% | 2 WSLH | ||
Hemoglobin A1c | Unclassified | 0,5, 5% | 7 RCPA | ||
Hemoglobin concentration | Unclassified | 3 g/L, 3% | 7 RCPA | ||
Hemoglobin - Qualitative | Unclassified | Urine | 80% Agreement | 3 NYS | |
Hemoglobin - Total | Unclassified | 7% | 2 WSLH | ||
Hemoglobin,Total A1 | Unclassified | 1,0 or 25% | 2 WSLH | ||
Hepatitis (Anti-HBc HBsAg HBeAg Anti-HCV ) | Unclassified | Reactive (Positive) or Nonreactive (Negative) | 3 NYS | ||
Hepatitis (HBsAg, anti-HBc, HBeAg) | Immunology | Reactive (positive) or nonreactive (negative) | 1 CLIA | ||
Heterophile | unclassified | Positive or Negative or +/- 2 dilutions | 3 NYS | ||
high sensitivity CRP | Unclassified | 0,4 mg/L or 3 SD% | 6 AAB | ||
high sensitivity CRP | Unclassified | BNII | not evaluated | 4 CAP | |
high sensitivity CRP | Unclassified | 2,0 SD | 2 WSLH | ||
HMMA | Unclassified | 20 umol/day, 20% | 7 RCPA | ||
Homocysteine | Unclassified | Non-graded analyte | 3 NYS | ||
Homocysteine | Unclassified | IMX | 3 SD | 4 CAP | |
Homocysteine | Unclassified | 2,5 umol/L or 20% | 6 AAB | ||
Homocysteine | Unclassified | Plasma | 17,70% | 5 BV | |
Homocysteine | Unclassified | 15% | 8 CFX | ||
Human Chorionic Gonadotropin | Endocrinology | +/- 3 SD or (positive or negative) | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Human Chorionic Gonadotropin | Unclassified | 3SD | 6 AAB | ||
HVA | Unclassified | 8 umol/day, 25% | 7 RCPA | ||
Hydroxiproline/creatinine | Unclassified | Serum | 32,90% | 5 BV | |
Hydroxiproline/minute, night | Unclassified | Urine | 0,43% | 5 BV | |
Hydroxyproline | Unclassified | Urine | 10 umol/L, 10% | 7 RCPA | |
IBC - Total | Unclassified | 25% | 8 CFX | ||
IBC - Unsaturated | Unclassified | 2 SD | 8 CFX | ||
IgA | Immunology | +/- 3 SD | 1 CLIA, 3 NYS, 6 AAB | ||
IgA | Unclassified | Blood | BNII | 3 SD | 4 CAP |
IgB | Immunology | +/- 3 SD | 1 CLIA | ||
IgE | Unclassified | 4,0 IU/L, 20% | 7 RCPA | ||
IgE | Unclassified | Opt | 3SD | 6 AAB | |
IgE | Unclassified | 3SD | 6 AAB | ||
IgE | Unclassified | +/- 3 SD | 3 NYS | ||
IGF-1 | Unclassified | 3 nmol/L, 15% | 7 RCPA | ||
IgG | Immunology | +/- 25% | 1 CLIA, 3 NYS, 6 AAB | ||
IgG | Unclassified | Blood | BNII | 3 SD | 4 CAP |
IgG | Unclassified | Cerebrospinal Fluid | BNII | 3 SD | 4 CAP |
IgG | Unclassified | Blood | BNII | 25% | 4 CAP |
IgM | Immunology | +/- 3 SD | 1 CLIA, 3 NYS, 6 AAB | ||
IgM | Unclassified | Blood | BNII | 3 SD | 4 CAP |
Imipramine | Unclassified | 15% | 8 CFX | ||
Immunofix | Unclassified | Urine | Sebia Hydrasis LS | 90% consensus | 4 CAP |
Immunofixation | Unclassified | Serum | Sebia Hydrasis LS | 90% consensus | 4 CAP |
Immunoglobin G | Unclassified | Cerebrospinal Fluid | 0,1 g/L, 10% | 7 RCPA | |
Immunoglobulin A | Unclassified | Serum | 13,50% | 5 BV | |
Immunoglobulin G | Unclassified | Serum | 8% | 5 BV | |
Immunoglobulin M | Unclassified | Serum | 16,80% | 5 BV | |
Immunoglobulins K chain | Unclassified | Serum | 8% | 5 BV | |
Immunoglobulins l chain | Unclassified | Serum | 8,60% | 5 BV | |
Infectious mononucleosis | Immunology | Target value +/- 2 dilution or (pos. or neg.) | 1 CLIA | ||
INR | Unclassified | 2 SD | 2 WSLH | ||
Insulin | Unclassified | 5 mU/L, 25% | 7 RCPA | ||
Insulin | Unclassified | +/-25% or 3,0 uU/mL | 3 NYS | ||
Insulin | Unclassified | Serum | 32,90% | 5 BV | |
Interferon receptor | Unclassified | Blood-Leukocyte | 17,70% | 5 BV | |
Interleukin-1B | Unclassified | Serum | 36,50% | 5 BV | |
Interleukin-8 | Unclassified | Serum | 29,60% | 5 BV | |
Ionised Calcium | Unclassified | 0,05 mmol/L | 7 RCPA | ||
Ionized Calcium | Unclassified | 0,25 mmol/L | 6 AAB | ||
Ionized Calcium | Unclassified | 0,13 mmol/L | 2 WSLH | ||
Iron | Unclassified | 5 umol/L | 7 RCPA | ||
Iron | Unclassified | 31% | 8 CFX | ||
Iron | Unclassified | Blood-Leukocyte | 30,70% | 5 BV | |
Iron | Unclassified | AU640 | 20% | 4 CAP | |
Iron | Unclassified | 20% | 6 AAB | ||
Iron Binding Capacity | Unclassified | 20% | 2 WSLH | ||
Iron Binding Capacity | Unclassified | AU640 | 20% | 4 CAP | |
Iron Saturation | Unclassified | Calculated | 3 SD | 4 CAP | |
Iron, total | Chimie | +/- 20% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Isopropanol | Unclassified | HP GLC | not evaluated | 4 CAP | |
Ketones - Qualitative | Unclassified | Urine | 80% Agreement | 3 NYS | |
Lactate | Unclassified | AU640 | 2 SD | 4 CAP | |
Lactate | Unclassified | 1,0 mmol/L, 10% | 7 RCPA | ||
Lactate | Unclassified | 1,0 mmol/day, 10% | 7 RCPA | ||
Lactate | Unclassified | 0,2 mmol/L or 2SD | 2 WSLH | ||
Lactate | Unclassified | Blood | 30,40% | 5 BV | |
Lactate | Unclassified | 3% | 8 CFX | ||
Lactate | Unclassified | Radiometer 725 | 4 CAP | ||
Lactate | Unclassified | Cerebrospinal Fluid | 0,1 mmol/L, 10% | 7 RCPA | |
Lactate Dehydrogenase (LDH) | Unclassified | 30 U/L, 15% | 7 RCPA | ||
Lactate Dehydrogenase (LDH) | Unclassified | AU640 | 20% | 4 CAP | |
Lactate Dehydrogenase (LDH) | Unclassified | 20% | 6 AAB | ||
Lactate Dehydrogenase (LDH) | Unclassified | 20% | 8 CFX | ||
Lactate Dehydrogenase (LDH) | Chimie | +/- 20% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Lactate Dehydrogenase (LDH) | Chimie | Serum | 0,114 | 5 BV | |
Lactate dehydrogenase 1 isoform (LDH1) | Unclassified | Serum | 8,20% | 5 BV | |
Lactate dehydrogenase 2 isoform (LDH2) | Unclassified | Serum | 5,70% | 5 BV | |
Lactate dehydrogenase 3 isoform (LDH3) | Unclassified | Serum | 5,80% | 5 BV | |
Lactate dehydrogenase 4 isoform (LDH4) | Unclassified | Serum | 11% | 5 BV | |
Lactate dehydrogenase 5 isoform (LDH5) | Unclassified | Serum | 14,80% | 5 BV | |
Lactoferrin | Unclassified | Opt | 0,5 mg/mL or 20% | 6 AAB | |
Lactoferrin | Unclassified | Plasma | 16,40% | 5 BV | |
LD Isoenzymes 3-5 | Unclassified | 3,00% or 30% | 6 AAB | ||
LDH isoenzymes | Chimie | LDH1/LDH2 (+ or -) or Target value +/- 30% | 1 CLIA, 3 NYS | ||
LDL Cholesterol | Unclassified | Serum | 13,60% | 5 BV | |
LDL- Cholesterol | Unclassified | AU640 | 20% | 4 CAP | |
LDL Cholesterol - Direct | Unclassified | 15 mg/dL or 20% | 6 AAB | ||
LDL receptor mRNA | Unclassified | Serum | 24,10% | 5 BV | |
Lead | Toxicologie | Blood | +/- 10% or +/- 4 mcg/dL (greater) | 1 CLIA, 2 WSLH | |
Lead | Unclassified | Blood | Spectra AA | 10% or 4 ug/dL (greater) | 4 CAP |
Leukocytes | Unclassified | 15% | 6 AAB | ||
Leukocytes, count | Hématologie | +/- 15% | 1 CLIA | ||
Leukocytes, count | Unclassified | Plasma | 14,60% | 5 BV | |
Luteinizing Hormone (LH) | Unclassified | Centaur | 3 SD | 4 CAP | |
Luteinizing Hormone (LH) | Unclassified | 2,5 SD | 2 WSLH | ||
Luteinizing Hormone (LH) | Unclassified | 2,0 IU/L, 20% | 7 RCPA | ||
Luteinizing Hormone (LH) | Unclassified | +/-25% or 1,5 IU/L | 3 NYS | ||
Lignocaine | Unclassified | 2,0 umol/L, 10% | 7 RCPA | ||
Lipase | Unclassified | 40 U/L, 20% | 7 RCPA | ||
Lipase | Unclassified | 37% | 8 CFX | ||
Lipase | Unclassified | 30% | 2 WSLH | ||
Lipase | Unclassified | AU640 | 30% | 4 CAP | |
Lipase | Unclassified | 30% | 6 AAB | ||
Lipase | Unclassified | Serum | 29,10% | 5 BV | |
Lipoprotein (a) | Unclassified | 2 SD | 8 CFX | ||
Lipoprotein (a) | Unclassified | 10 mg/dL or 30% | 6 AAB | ||
Lipoprotein (a) | Unclassified | Serum | 28,80% | 5 BV | |
Lithium | Toxicologie | AVL 9180 | 20% or 0,3 mEq/L (greater) | 4 CAP | |
Lithium | Toxicologie | 0,2 mmol/L | 7 RCPA | ||
Lithium | Toxicologie | +/- 20% or 0,3 mmol/L | 1 CLIA, 2 WSLH, 6 AAB | ||
Lithium | Toxicologie | +/- 15% or 0,3 mmol/L | 3 NYS | ||
Lithium | Toxicologie | 10% | 8 CFX | ||
Luteinizing Hormone (LH) | Unclassified | 2 SD | 8 CFX | ||
Luteinizing Hormone (LH) | Unclassified | 2 mIU/mL or 25% | 6 AAB | ||
Luteinizing Hormone (LH) | Unclassified | Serum | 19,80% | 5 BV | |
Lymphocytes, count | Unclassified | Blood | 16% | 5 BV | |
Magnesium | Chimie | 3 mmol/L | 7 RCPA | ||
Magnesium | Chimie | 0,1 mmol/L, 12% | 8 CFX | ||
Magnesium | Chimie | +/- 25% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Magnesium | Chimie | Blood-Leukocyte | 21,20% | 5 BV | |
Magnesium | Chimie | Blood-Erythrocytes | 7,80% | 5 BV | |
Magnesium | Chimie | Serum | 4,80% | 5 BV | |
Magnesium | Unclassified | AU640 | 25% | 4 CAP | |
Magnesium | Unclassified | Urine | 25% | 2 WSLH | |
Magnesium | Unclassified | Urine | AU640 | 25% | 4 CAP |
Magnesium - Ionized | Unclassified | 10% | 8 CFX | ||
Magnesium (serum) | Unclassified | Urine | 0,12 mmol/L | 7 RCPA | |
Magnesium - Concentration, 24h | Unclassified | Urine | 52,20% | 5 BV | |
Magnesium, ionized | Unclassified | Urine | 2,90% | 5 BV | |
Magnesium - Output, 24h | Unclassified | Urine | 45% | 5 BV | |
Mean corpuscular hemoglobin (HCM) | Unclassified | Blood-Erythrocytes | 2,70% | 5 BV | |
Mean corpuscular hemoglobin concentration | Unclassified | Blood-Erythrocytes | 2,20% | 5 BV | |
Mean corpuscular volume (MCV) | Unclassified | 3 SD | 2 WSLH | ||
Mean corpuscular volume (MCV) | Unclassified | Blood-Erythrocytes | 2,30% | 5 BV | |
Mean platelet volume (MPV) | Unclassified | Blood-Platelets | 5,80% | 5 BV | |
Metanephrine | Unclassified | 0,5 umol/day, 33% | 7 RCPA | ||
Methadone | Unclassified | Pos/Neg | 2 WSLH | ||
Methadone | Unclassified | 20% or 2 SD | 3 NYS | ||
Methanol | Unclassified | HP GLC | not evaluated | 4 CAP | |
Methemoglobin | Unclassified | 3 SD | 2 WSLH | ||
Methemoglobin | Unclassified | Radiometer 725 | 2% | 4 CAP | |
Methotrexate | Unclassified | 0,1 umol/L, 10% | 7 RCPA | ||
Methotrexate | Unclassified | 25% | 8 CFX | ||
Methqualone | Unclassified | Pos/Neg | 2 WSLH | ||
Microalbumin | Unclassified | Urine | AU640 | 3 SD | 4 CAP |
Microalbumin | Unclassified | Urine | 10 mg/L or 25% | 6 AAB | |
Microalbumin - Quantitative | Unclassified | 2,5 SD | 2 WSLH | ||
Monocytes, count | Unclassified | Blood | 27,90% | 5 BV | |
M-Protein Interpr. | Unclassified | Sebia Hydrasis LS | 90% consensus | 4 CAP | |
MSAFP | Unclassified | Centaur | 3 SD | 4 CAP | |
MShCG | Unclassified | Centaur | 3 SD | 4 CAP | |
Mucinous carcinoma-associated antigen (M | Unclassified | Serum | 18,50% | 5 BV | |
Myoglobin | Unclassified | 15 ng/mL or 30% | 6 AAB | ||
Myoglobin | Unclassified | 30% | 8 CFX | ||
Myoglobin | Unclassified | Serum | 19,60% | 5 BV | |
Myoglobin - Qualitative | Unclassified | Pos/Neg | 2 WSLH | ||
Myoglobin - Quantitative | Unclassified | 2 SD | 2 WSLH | ||
N-Acetyl Glucosaminidase - Concentration | Unclassified | Urine | 53,10% | 5 BV | |
N-Acetyl Glucosaminidase - Output | Unclassified | Urine | 46,50% | 5 BV | |
N-Acetyl procainamide | Unclassified | +/- 15% | 3 NYS | ||
N-Acetyl procainamide | Unclassified | Abbott AxSym | 25% | 4 CAP | |
N-Acetyl procainamide | Unclassified | 20% | 8 CFX | ||
Napa | Unclassified | Abbott AxSym | 25% | 4 CAP | |
Neutrophyles, count | Unclassified | Blood | 22,40% | 5 BV | |
Nitrogen - Output | Unclassified | Urine | 18,40% | 5 BV | |
Noradrenaline | Unclassified | 50 nmol/day, 10% | 7 RCPA | ||
Normetanephrine | Unclassified | 1,0 umol/day, 33% | 7 RCPA | ||
Nortriptyline | Unclassified | 10 nmol/L, 10% | 7 RCPA | ||
Nortriptyline | Unclassified | 15% | 8 CFX | ||
NSE | Unclassified | 2,0 ug/L, 10% | 7 RCPA | ||
N-Telopeptides | Unclassified | Urine | 80 nmolBCE/L, 10% | 7 RCPA | |
Oestradiol | Unclassified | 100 pmol/L, 20% | 7 RCPA | ||
Oestriol - Total | Unclassified | 20 nmol/L, 10% | 7 RCPA | ||
Oestriol - Unconjugated | Unclassified | 5 nmol/L, 20% | 7 RCPA | ||
Oligoclonal Bands | Unclassified | Sebia Hydrasis LS | 90% consensus | 4 CAP | |
Opiates | Unclassified | Abbott AxSym | 80% consensus | 4 CAP | |
Opiates | Unclassified | Pos/Neg | 2 WSLH | ||
Opiates | Unclassified | 20% or 2 SD | 3 NYS | ||
Osmolality | Unclassified | Urine | 9. mOsm/kg or 10% | 6 AAB | |
Osmolality | Unclassified | 8 mmol/kg | 7 RCPA | ||
Osmolality | Unclassified | Freezing point | 2 SD | 4 CAP | |
Osmolality | Unclassified | 3% | 8 CFX | ||
Osmolality | Unclassified | Serum | 1,50% | 5 BV | |
Osmolality | Unclassified | Urine | Freezing point | 3 SD | 4 CAP |
Osmolality | Unclassified | Serum | 3 SD | 2 WSLH | |
Osmolality | Unclassified | Urine | 3 SD | 2 WSLH | |
Osmolality | Unclassified | Urine | 6 mmol/kg, 2% | 7 RCPA | |
Osteocalcin | Unclassified | Serum | 11,20% | 5 BV | |
Oxalate - Concentration | Unclassified | Urine | 48,20% | 5 BV | |
Oxalate - Output | Unclassified | Urine | 46,80% | 5 BV | |
Oxyhemoglobin | Unclassified | 3 SD | 2 WSLH | ||
Oxyhemoglobin | Unclassified | Radiometer 725 | 4 CAP | ||
PAP | Unclassified | 2,5 SD | 2 WSLH | ||
Paracetamol | Unclassified | 20 umol/L, 10% | 7 RCPA | ||
Partial thromboplastin time | Hématologie | +/- 15% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
pCO2 | Unclassified | Radiometer 725 | 8% or 5 mm Hg (greater) | 4 CAP | |
pCO2 | Unclassified | 5,0 mm Hg or 8% | 6 AAB | ||
pCO2 | Unclassified | 5 kPa, 8% | 8 CFX | ||
pCO2 | Unclassified | 2,0 mm Hg, 8% | 7 RCPA | ||
pCO2 | Unclassified | Blood | 5,70% | 5 BV | |
pH | Unclassified | Radiometer 725 | 4% | 4 CAP | |
pH | Unclassified | 4% | 6 AAB | ||
pH | Unclassified | 4% | 7 RCPA | ||
pH | Unclassified | 4% | 8 CFX | ||
pH [H+] | Unclassified | Blood | 3,90% | 5 BV | |
pH - Qualitative | Unclassified | Urine | 80% Agreement | 3 NYS | |
pH,Fluid | Unclassified | Corning 445 pH meter | 4% | 4 CAP | |
Phencyclidine | Unclassified | Pos/Neg | 2 WSLH | ||
Phencyclidine | Unclassified | Abbott AxSym | 80% consensus | 4 CAP | |
Phencyclidine | Unclassified | 20% or 2 SD | 3 NYS | ||
Phenobarbital | Toxicologie | +/- 20% | 1 CLIA, 2 WSLH, 6 AAB | ||
Phenobarbital | Toxicologie | +/- 15% | 3 NYS | ||
Phenobarbital | Toxicologie | Abbott AxSym | 20% | 4 CAP | |
Phenobarbital | Toxicologie | 20% | 8 CFX | ||
Phenobarbitone | Unclassified | 3,0 umol/L, 10% | 7 RCPA | ||
Phenytoin | Toxicologie | 3,0 umol/L, 10% | 7 RCPA | ||
Phenytoin | Toxicologie | +/- 25% | 1 CLIA, 2 WSLH, 6 AAB | ||
Phenytoin | Toxicologie | +/- 15% | 3 NYS | ||
Phenytoin | Toxicologie | Abbott AxSym | 25% | 4 CAP | |
Phenytoin | Toxicologie | 25% | 8 CFX | ||
Phenytoin - Free | Unclassified | TDX | 3 SD | 4 CAP | |
Phosphate | Unclassified | 0,1 mmol/L, 10% | 7 RCPA | ||
Phosphate | Unclassified | Serum | 10,20% | 5 BV | |
Phosphate | Unclassified | Urine | 2,5 mmol/L | 7 RCPA | |
Phosphate tubular reabsorption | Unclassified | Patient- | 3,30% | 5 BV | |
Phosphate - Concentration | Unclassified | Urine | 31,10% | 5 BV | |
Phosphate - Output | Unclassified | Urine | 22,10% | 5 BV | |
Phospholipids | Unclassified | Serum | 8,60% | 5 BV | |
Phosphorus | Unclassified | Urine | 3. mg/dL or 15% | 6 AAB | |
Phosphorus | Unclassified | AU640 | 10,7% or 0,3 mg/dL (greater) | 4 CAP | |
Phosphorus | Unclassified | 0,5 mg/dL or 12% | 2 WSLH | ||
Phosphorus | Unclassified | 0,4 mg/dL or 15% | 6 AAB | ||
Phosphorus | Unclassified | +/- 0,45 mg/dL or 13% | 3 NYS | ||
Phosphorus | Unclassified | 12% | 8 CFX | ||
Phosphorus | Unclassified | Urine | 0,5 mg/dL or 12% | 2 WSLH | |
Phosphorus | Unclassified | Urine | AU640 | 23% | 4 CAP |
Plasma Renin Activity | Unclassified | 1,0 ng/mL/hr, 25% | 7 RCPA | ||
Plasma Total Porphyrin | Unclassified | 3 nmol/L, 15% | 7 RCPA | ||
Platelet count | Hématologie | +/- 25% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Platelet, count | Unclassified | Blood | 13,40% | 5 BV | |
Platelets | Unclassified | 25% | 6 AAB | ||
pO2 | Unclassified | 5 mm Hg, 5% | 7 RCPA | ||
pO2 | Unclassified | 3SD | 6 AAB | ||
pO2 | Unclassified | Radiometer 725 | 3 SD | 4 CAP | |
pO2 | Unclassified | 2 SD | 8 CFX | ||
Polylysine | Unclassified | 45 mmol/L or 30% | 6 AAB | ||
Potassium | Chimie | Radiometer 725 | 0,5 mmol/L | 4 CAP | |
Potassium | Chimie | 0,2 mmol/L | 7 RCPA | ||
Potassium | Chimie | +/- 0,5 mmol/L | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Potassium | Chimie | Blood-Leukocyte | 16% | 5 BV | |
Potassium | Chimie | 6% | 8 CFX | ||
Potassium | Chimie | Serum | 5,80% | 5 BV | |
Potassium | Unclassified | AU640 | 0,5 mmol/L | 4 CAP | |
Potassium | Unclassified | Urine | 2 SD | 2 WSLH | |
Potassium | Unclassified | Urine | AU640 | 29% | 4 CAP |
Potassium | Unclassified | Urine | 2,0 mmol/L, 10% | 7 RCPA | |
Potassium - Concentration | Unclassified | Urine | 31,30% | 5 BV | |
Potassium - Output | Unclassified | Urine | 28,40% | 5 BV | |
Potassium - POCT | Unclassified | POCT | 2,0 mmol/L | 7 RCPA | |
Prealbumin | Unclassified | BNII | 25% or 5 mg/dL (greater) | 4 CAP | |
Prealbumin | Unclassified | Serum | 14,50% | 5 BV | |
Prealbumin | Unclassified | 2,5 SD | 2 WSLH | ||
Pregnancy | Unclassified | Serum | pos/neg | 6 AAB | |
Primidone | Toxicologie | +/- 25% | 1 CLIA, 2 WSLH, 6 AAB | ||
Primidone | Toxicologie | +/- 15% | 3 NYS | ||
Primidone | Toxicologie | 15% | 8 CFX | ||
Procainamide | Unclassified | +/- 15% | 3 NYS | ||
Procainamide | Unclassified | Abbott AxSym | 25% | 4 CAP | |
Procainamide | Unclassified | 25% | 6 AAB | ||
Procainamide | Unclassified | 20% | 8 CFX | ||
Procainamide (and metabolite) | Toxicologie | +/- 25% | 1 CLIA, 2 WSLH, 6 AAB | ||
Procainamide, N-Acetyl (NAPA) | Unclassified | 25% | 6 AAB | ||
Procollagen type 1 N-terminal | Unclassified | Serum | 10,50% | 5 BV | |
Progesterone | Unclassified | 300 pg/mL or 30% | 2 WSLH | ||
Progesterone | Unclassified | Centaur | 3 SD | 4 CAP | |
Progesterone | Unclassified | 2 SD | 8 CFX | ||
Progesterone | Unclassified | 2 nmol/L, 25% | 7 RCPA | ||
Progesterone | Unclassified | 0,3 ng/mL or 30% | 6 AAB | ||
Progesterone | Unclassified | +/-25% or 1,0 ng/mL | 3 NYS | ||
Prolactin | Unclassified | 3,6 ng/mL or 30% | 2 WSLH | ||
Prolactin | Unclassified | 3,6 ng/mL or 30% | 6 AAB | ||
Prolactin | Unclassified | Centaur | 3 SD | 4 CAP | |
Prolactin | Unclassified | 20 mU/L, 20% | 7 RCPA | ||
Prolactin | Unclassified | 2 SD | 8 CFX | ||
Prolactin | Unclassified | +/-25% or 1,0 ug/L | 3 NYS | ||
Prolactin (men) | Unclassified | Serum | 21,10% | 5 BV | |
Prolyl endopeptidase | Unclassified | Plasma | 19,30% | 5 BV | |
Propoxyphene | Unclassified | Pos/Neg | 2 WSLH | ||
Propoxyphene | Unclassified | 20% or 2 SD | 3 NYS | ||
Prostatic Specific Antigen (PSA) | Unclassified | 0,9 ng/mL or 30% | 6 AAB | ||
Prostatic Specific Antigen (PSA) | Unclassified | Serum | 30% | 5 BV | |
Protein | Unclassified | 10% | 2 WSLH | ||
Protein - Total | Unclassified | 6% | 8 CFX | ||
Protein - Total | Unclassified | 5,0 g/L | 7 RCPA | ||
Protein - Total | Unclassified | AU640 | 10% | 4 CAP | |
Protein - Total | Unclassified | Serum | 3,40% | 5 BV | |
Protein - Total | Unclassified | Urine | 80% Agreement | 3 NYS | |
Protein - Total | Unclassified | Urine | 10% | 2 WSLH | |
Protein C | Unclassified | Serum | 18,70% | 5 BV | |
Protein Electrophoresis Interpretation | Unclassified | Urine | Sebia Hydrasis LS | 90% consensus | 4 CAP |
Protein Electrophoresis Interpretation | Unclassified | Serum | Sebia Hydrasis LS | 90% consensus | 4 CAP |
Protein Electrophoresis Interpretation (24 Hour) | Unclassified | Urine | Sebia Hydrasis LS | 90% consensus | 4 CAP |
Protein S | Unclassified | Plasma | 20,70% | 5 BV | |
Protein - Concentration | Unclassified | Urine | 43,50% | 5 BV | |
Protein- Output | Unclassified | Urine | 40% | 5 BV | |
Prothrombin Time | Hématologie | +/- 15% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Prothrombin Time | Hématologie | Plasma | 5,30% | 5 BV | |
Prothrombin Time | Unclassified | CoaguChek | 15% | 6 AAB | |
Prothrombin Time | Unclassified | 15% | 6 AAB | ||
Prothrombin Time | Unclassified | Whole Blood | 15% | 6 AAB | |
PSA | Unclassified | Abbott AxSym | 3 SD | 4 CAP | |
PSA | Unclassified | 0,9 ng/mL or 30% | 2 WSLH | ||
PSA | Unclassified | +/- 3 SD | 3 NYS | ||
PSA - Free | Unclassified | 0,9 ng/mL or 30% | 2 WSLH | ||
PTH | Unclassified | Centaur | 3 SD | 4 CAP | |
PTH | Unclassified | 2,5 pmol/L, 25% | 7 RCPA | ||
Pyridinoline/creatinine, morning spot | Unclassified | Urine | 12,10% | 5 BV | |
Pyruvate | Unclassified | Blood | 17,50% | 5 BV | |
Qualitative hCG | Unclassified | Positive or Negative | 3 NYS | ||
Quinidine | Toxicologie | 2,0 umol/L, 10% | 7 RCPA | ||
Quinidine | Toxicologie | +/- 25% | 1 CLIA, 2 WSLH, 6 AAB | ||
Quinidine | Toxicologie | +/- 15% | 3 NYS | ||
Quinidine | Toxicologie | Abbott AxSym | 25% | 4 CAP | |
Quinidine | Toxicologie | 25% | 8 CFX | ||
RBC Folate | Unclassified | 2,5 SD | 2 WSLH | ||
RBC Total Porphyrin | Unclassified | 0,3 umol/L rc, 15% | 7 RCPA | ||
Red cell distribution wide | Unclassified | Blood | 4,60% | 5 BV | |
Reticulocyte Count | Unclassified | 0,50% or 30% | 6 AAB | ||
Reticulocyte highly fluorescent, count | Unclassified | Serum | 24% | 5 BV | |
Reticulocyte low fluorescent, count | Unclassified | Serum | 2,60% | 5 BV | |
Reticulocyte medium fluorescent, count | Unclassified | Serum | 19,60% | 5 BV | |
Reticulocyte, count | Unclassified | Serum | 16,80% | 5 BV | |
Reticulocytes | Unclassified | 3 SD | 2 WSLH | ||
Retinol | Unclassified | Serum | 18,10% | 5 BV | |
Rheumatoid Factor | Immunology | Target value +/- 2 dilution or (pos. or neg.) | 1 CLIA | ||
Rheumatoid Factor | Immunology | Serum | 13,50% | 5 BV | |
Rheumatoid Factor | Unclassified | Positive or Negative or +/- 2 dilutions | 3 NYS | ||
Rheumatoid Factor | Unclassified | BNII | 2 SD | 4 CAP | |
Rubella | Immunology | Target value +/- 2 dilution or (pos. or neg.) | 1 CLIA | ||
Salicylates | Unclassified | 0,1 mmol/L, 10% | 7 RCPA | ||
Salicylates | Unclassified | +/- 15% | 3 NYS | ||
Salicylates | Unclassified | 25% | 2 WSLH | ||
Salicylates | Unclassified | AU640 | 3 SD | 4 CAP | |
Salicylates | Unclassified | 25% | 6 AAB | ||
Salicylates | Unclassified | 20% | 8 CFX | ||
SCC antigen | Unclassified | Serum | 45,80% | 5 BV | |
Sedimentation Rate [ESR] | Unclassified | 2,5 SD | 2 WSLH | ||
Selenium | Unclassified | Blood | 14,50% | 5 BV | |
Selenium | Unclassified | Plasma | 14,50% | 5 BV | |
Serotonin | Unclassified | 0,3 umol/day, 30% | 7 RCPA | ||
Sex hormone binding globulin (SHBG) | Unclassified | Serum | 21,10% | 5 BV | |
SHBG | Unclassified | 5 nmol/L, 10% | 7 RCPA | ||
Sickle Cell Screen | Unclassified | Pos/Neg | 2 WSLH | ||
Sodium | Chimie | 4 mmol/L, 5% | 8 CFX | ||
Sodium | Chimie | Radiometer 725 | 4 mmol/L | 4 CAP | |
Sodium | Chimie | AU640 | 4 mmol/L | 4 CAP | |
Sodium | Chimie | 3,0 mmol/L | 7 RCPA | ||
Sodium | Chimie | +/- 4 mmol/L | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Sodium | Chimie | Blood-Leukocyte | 0,577 | 5 BV | |
Sodium | Chimie | Blood-Erythrocytes | 0,046 | 5 BV | |
Sodium | Chimie | Serum | 0,009 | 5 BV | |
Sodium | Unclassified | Urine | 2 SD | 2 WSLH | |
Sodium | Unclassified | Urine | AU640 | 26% | 4 CAP |
Sodium | Unclassified | Sweat | 2 mmol/L, 10% | 7 RCPA | |
Sodium | Unclassified | Urine | 2,0 mmol/L, 10% | 7 RCPA | |
Sodium - Concentration | Unclassified | Urine | 28,80% | 5 BV | |
Sodium - Output | Unclassified | Urine | 32% | 5 BV | |
Specific Gravity | Unclassified | Urine | 1% | 6 AAB | |
Specific Gravity - Qualitative | Unclassified | Urine | 80% Agreement | 3 NYS | |
Sperm Count | Unclassified | 3 million/mL or 25% | 6 AAB | ||
Sperm Morphology | Unclassified | 5% normal or 20%% | 6 AAB | ||
Sperm Viability | Unclassified | 5% viable or 20%% | 6 AAB | ||
Superoxide dismutase | Unclassified | Serum | 19,10% | 5 BV | |
Superoxide dismutase | Unclassified | Blood-Erythrocytes | 13,50% | 5 BV | |
Sweat Conductivity | Unclassified | 2 mmol/L, 10% | 7 RCPA | ||
T Uptake | Unclassified | 7% | 8 CFX | ||
T3 uptake | Endocrinology | +/- 3 SD by method | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
T3 Uptake | Unclassified | Centaur | 3 SD | 4 CAP | |
T3, T3 | Unclassified | Centaur | 3 SD | 4 CAP | |
T3-uptake | Unclassified | Serum | 5,30% | 5 BV | |
T4, Free | Unclassified | Centaur | 3 SD | 4 CAP | |
T4, Total | Unclassified | Centaur | 20% or 1 ug/dL (greater) | 4 CAP | |
Tacrolimus (FK 506) | Unclassified | IMX | 3 SD | 4 CAP | |
Testosterone | Unclassified | Centaur | 3 SD | 4 CAP | |
Testosterone | Unclassified | 2 SD | 8 CFX | ||
Testosterone | Unclassified | 0,5 nmol/L, 20% | 7 RCPA | ||
Testosterone | Unclassified | 0,3 ng/mL or 30% | 2 WSLH | ||
Testosterone | Unclassified | 0,3 ng/mL or 30% | 6 AAB | ||
Testosterone | Unclassified | +/-25% or 1,0 ng/dL | 3 NYS | ||
Testosterone | Unclassified | Saliva | 22,70% | 5 BV | |
Testosterone | Unclassified | Serum | 14% | 5 BV | |
Testosterone - Free | Unclassified | 0,3 ng/mL or 30% | 2 WSLH | ||
THC-cannabinoids | Unclassified | 20% or 2 SD | 3 NYS | ||
Theophylline | Toxicologie | 3,0 umol/L, 10% | 7 RCPA | ||
Theophylline | Toxicologie | +/- 25% | 1 CLIA, 2 WSLH, 6 AAB | ||
Theophylline | Toxicologie | +/- 15% | 3 NYS | ||
Theophylline | Toxicologie | Abbott AxSym | 25% | 4 CAP | |
Theophylline | Toxicologie | 25% | 8 CFX | ||
Thyroglobulin | Unclassified | Serum | 17,80% | 5 BV | |
Thyroid Stimulating Hormone (TSH) | Endocrinology | +/- 3 SD | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Thyroid Stimulating Hormone (TSH) | Unclassified | 3SD | 6 AAB | ||
Thyroid Stimulating Hormone (TSH) | Unclassified | 30% | 8 CFX | ||
Thyroid Stimulating Hormone (TSH) | Unclassified | Serum | 24,60% | 5 BV | |
Thyroxin binding globulin (TBG) | Unclassified | Serum | 7,10% | 5 BV | |
Thyroxine | Endocrinology | 8 nmol/L, 15% | 7 RCPA | ||
Thyroxine | Endocrinology | +/- 20% or 1,0 mcg/dL (greater) | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Thyroxine - Free | Unclassified | 2 SD | 8 CFX | ||
Thyroxine - Total | Unclassified | 8% | 8 CFX | ||
Thyroxine (T4) | Unclassified | Serum | 8,30% | 5 BV | |
Thyroxine - Free | Unclassified | 3SD | 6 AAB | ||
Thyroxine - Total | Unclassified | 1,0 µg/dL or 20% | 6 AAB | ||
TIBC | Unclassified | 10,0 umol/L | 7 RCPA | ||
TIBC | Unclassified | Centaur | 20% | 4 CAP | |
Tissue polypeptide antigen (TPA) | Unclassified | Serum | 36,10% | 5 BV | |
Tissue polypeptide specific antigen (TPS) | Unclassified | Serum | 58,30% | 5 BV | |
Tobramycin | Toxicologie | 0,5 mg/L, 10% | 7 RCPA | ||
Tobramycin | Toxicologie | +/- 25% | 1 CLIA, 2 WSLH, 6 AAB | ||
Tobramycin | Toxicologie | +/- 15% | 3 NYS | ||
Tobramycin | Toxicologie | Abbott AxSym | 25% | 4 CAP | |
Tobramycin | Toxicologie | 25% | 8 CFX | ||
Total Beta hCG | Unclassified | +/- 3 SD | 3 NYS | ||
Total Bilirubin, Neonatal | Unclassified | 15 umol/L, 10% | 7 RCPA | ||
Total Carotenoids | Unclassified | 0,4 umol/L, 10% | 7 RCPA | ||
Total catecolamines - Concentration, 24h | Unclassified | Urine | 29,80% | 5 BV | |
Total Estriol | Unclassified | +/-25% or 3,0 ng/mL | 3 NYS | ||
Total Glycated Hemoglobin | Unclassified | 1,2 or 20% | 2 WSLH | ||
Total Iron Binding Capacity (TIBC) | Unclassified | 25% | 6 AAB | ||
Total Protein | Chimie | +/- 10% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Total Protein | Unclassified | Urine | 1,0 mg/dL or 25% | 6 AAB | |
Total Protein | Unclassified | 10% | 6 AAB | ||
Total Protein | Unclassified | Urine | AU640 | 44% | 4 CAP |
Total Protein | Unclassified | Cerebrospinal Fluid | 0,1 g/L, 10% | 7 RCPA | |
Total Protein | Unclassified | Urine | 0,1 g/L, 10% | 7 RCPA | |
Total PSA | Unclassified | 1,5 ug/L, 15% | 7 RCPA | ||
Total T3 (Endocrinology) | Unclassified | 0,3 nmol/L, 20% | 7 RCPA | ||
Total T3 (General Chemistry) | Unclassified | 0,3 nmol/L, 15% | 7 RCPA | ||
Total T4 | Unclassified | 8 nmol/L, 15% | 7 RCPA | ||
Transferrin | Unclassified | 2,5 SD | 2 WSLH | ||
Transferrin | Unclassified | 0,5 g/L | 7 RCPA | ||
Transferrin | Unclassified | BNII | 20% | 4 CAP | |
Transferrin | Unclassified | 12% | 8 CFX | ||
Transferrin | Unclassified | Serum | 3,80% | 5 BV | |
Tricyclic Antidepressants | Unclassified | Pos/Neg | 2 WSLH | ||
Tricyclic Antidepressants | Unclassified | 20% or 2 SD | 3 NYS | ||
Tricyclic Antidepressants | Unclassified | 10 nmol/L, 10% | 7 RCPA | ||
Tricyclic Antidepressants | Unclassified | 15% | 8 CFX | ||
Triglycerides | Unclassified | 0,20 mmol/L, 10% | 7 RCPA | ||
Triglycerides | Unclassified | Serum | 27,90% | 5 BV | |
Triglycerides | Chimie | +/- 25% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Triglycerides | Chimie | AU640 | 25% | 4 CAP | |
Triglycerides | Chimie | 15% | 8 CFX | ||
Triiodothyronine | Endocrinology | +/- 3 SD | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Triiodothyronine - Free | Unclassified | 20% | 8 CFX | ||
Triiodothyronine - Total | Unclassified | 20% | 8 CFX | ||
Triiodothyronine (T3) | Unclassified | Serum | 11,40% | 5 BV | |
Triiodothyronine, Free (Free T3) | Unclassified | 1,5 pg/mL or 30% | 6 AAB | ||
Triiodothyronine, Total (T3) | Unclassified | 3SD | 6 AAB | ||
Troponin I | Unclassified | Centaur | not evaluated | 4 CAP | |
Troponin I | Unclassified | 2 SD | 8 CFX | ||
Troponin I | Unclassified | 0,9 ng/mL or 30% | 6 AAB | ||
Troponin I | Unclassified | 0,2 ng/mL, 10% | 7 RCPA | ||
Troponin I - Qualitative | Unclassified | Pos/Neg | 2 WSLH | ||
Troponin I - Quantitative | Unclassified | 2 SD | 2 WSLH | ||
Troponin T | Unclassified | 2 SD | 8 CFX | ||
Troponin T | Unclassified | 0,1 ng/mL, 10% | 7 RCPA | ||
Troponin T | Unclassified | 0,1 ng/mL or 30% | 6 AAB | ||
Troponin T - Qualitative | Unclassified | Pos/Neg | 2 WSLH | ||
Troponin T - Quantitative | Unclassified | 2 SD | 2 WSLH | ||
Thyroid Stimulating Hormone (TSH) | Unclassified | Centaur | 3 SD | 4 CAP | |
Thyroid Stimulating Hormone (TSH) | Unclassified | 0,6 mU/L, 15% | 7 RCPA | ||
Tumor Necrosis Factor-a | Unclassified | Serum | 48,40% | 5 BV | |
TUptake | Unclassified | 3SD | 6 AAB | ||
uE3 (Maternal Sera) | Unclassified | Maternal Sera | +/- 3 SD | 3 NYS | |
Unsaturated Iron Binding Capacity (UIBC) | Unclassified | 25% | 6 AAB | ||
Urate | Unclassified | 0,050 mmol/L | 7 RCPA | ||
Urate | Unclassified | Serum | 11,90% | 5 BV | |
Urate | Unclassified | Urine | 0,3 mmol/L | 7 RCPA | |
Urate - Concentration, 24h | Unclassified | Urine | 28,70% | 5 BV | |
Urate- Output, 24h | Unclassified | Urine | 21,10% | 5 BV | |
Urea | Unclassified | AU640 | 9% or 2 mg N/dL (greater) | 4 CAP | |
Urea | Unclassified | 0,1 mmol/L, 10% | 7 RCPA | ||
Urea | Unclassified | Serum | 15,70% | 5 BV | |
Urea | Unclassified | Urine | 20 mmol/L, 10% | 7 RCPA | |
Urea | Unclassified | Urine | AU640 | 21% | 4 CAP |
Urea Nitrogen | Chimie | +/- 2 mg/dL or +/- 9% (greater) | 1 CLIA | ||
Urea Nitrogen | Unclassified | Urine | 2 mg/dL or 9% | 2 WSLH | |
Urea - Concentration, 24h | Unclassified | Urine | 27,30% | 5 BV | |
Urea - Output, 24h | Unclassified | Urine | 22,10% | 5 BV | |
Urea/Urea Nitrogen | Unclassified | 16% | 8 CFX | ||
Urea-POCT | Unclassified | POCT | 1,0 mmol/L, 10% | 7 RCPA | |
Uric Acid | Chimie | +/- 17% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
Uric Acid | Unclassified | Urine | 17% | 6 AAB | |
Uric Acid | Unclassified | 17% | 6 AAB | ||
Uric Acid | Unclassified | 12% | 8 CFX | ||
Uric Acid | Unclassified | Urine | 17% | 2 WSLH | |
Uric Acid | Unclassified | Urine | AU640 | 24% | 4 CAP |
Uric Acid | Chimie | AU640 | 17% | 4 CAP | |
Urine ALA | Unclassified | 5 umol/L, 25% | 7 RCPA | ||
Urine Porphobilinogen - Quantitative | Unclassified | 5 umol/L, 20% | 7 RCPA | ||
Urine Total Porphyrin | Unclassified | 15 nmol/L, 15% | 7 RCPA | ||
Valproate | Unclassified | 25 umol/L, 10% | 7 RCPA | ||
Valproic Acid | Toxicologie | +/- 25% | 1 CLIA, 2 WSLH, 6 AAB | ||
Valproic Acid | Toxicologie | +/- 15% | 3 NYS | ||
Valproic Acid | Unclassified | Abbott AxSym | 25% | 4 CAP | |
Valproic Acid | Unclassified | 25% | 6 AAB | ||
Valproic Acid | Unclassified | 15% | 8 CFX | ||
Valproic Acid, free | Unclassified | TDX | 3 SD | 4 CAP | |
Vancomycin | Unclassified | Abbott AxSym | 3 SD | 4 CAP | |
Vancomycin | Unclassified | 2,0 mg/L, 10% | 7 RCPA | ||
Vancomycin | Unclassified | 1,5 ug/mL or 25% | 6 AAB | ||
Vancomycin | Unclassified | +/- 15% | 3 NYS | ||
Vancomycin | Unclassified | 25% | 2 WSLH | ||
Vancomycin | Unclassified | 20% | 8 CFX | ||
Vanilmandelic Acid concentration, 24h | Unclassified | Urine | 31,30% | 5 BV | |
Vitamin A | Unclassified | 0,3 umol/L, 10% | 7 RCPA | ||
Vitamin B-12 | Unclassified | 60 pg/mL or 30% | 2 WSLH | ||
Vitamin B-12 | Unclassified | 60 pg/mL or 30% | 6 AAB | ||
Vitamin B-12 | Unclassified | 20 pmol/L, 20% | 7 RCPA | ||
Vitamin B-12 | Unclassified | +/- 25% | 3 NYS | ||
Vitamin B-12 | Unclassified | Centaur | 3 SD | 4 CAP | |
Vitamin D3 | Unclassified | 5 nmol/L, 15 | 7 RCPA | ||
Vitamin E | Unclassified | 5,0 umol/L, 10% | 7 RCPA | ||
Von Willebrand factor | Unclassified | Plasma | 7,40% | 5 BV | |
Water | Unclassified | Serum | 3,30% | 5 BV | |
White cell differentiation | Hématologie | Target +/- 3 SD based on percentage of different types of white cells | 1 CLIA, 2 WSLH | ||
Zinc | Unclassified | Serum | 13,50% | 5 BV | |
Zinc | Unclassified | Plasma | 11% | 5 BV | |
ZPP | Unclassified | +/-15% (µmol/mol heme) | 3 NYS |
Abbreviations and Sources
Abbreviation | Source |
---|---|
1 CLIA | CLIA ’88, CLIA |
2 WLSH | Wisconsin State Laboratory of Hygiene |
3 NYS | Wadsworth Center of the New York State Department of Health |
4 CAP | College of American Pathologists (CAP) |
5 BV | 2004 update of the Spanish Society of Clinical Chemistry and Molecular Pathology (SEQC) table of Desirable Quality Specifications based on Biological Variation. |
6 AAB | American Association of Bioanalysts (AAB) |
7 RCPA | The Royal College of Pathologists of Australasia and the Australasian Clinical Biochemist association Quality Assurance Program |
8 CFX | Canadian Fixed limits from the College of Physicians and Surgeons of Saskatchewan |